Boybabyrage personal page - To The Moon

Boybabyrage

Boybabyrage

Come here to make some coffee money 🤑

31Follow

39Followers

0Topic

0Badge

04-16

Trump needs to be stopped

Sorry, the original content has been removed

04-08

The black tiger mug looks cool 😎

04-02

$Johnson & Johnson(JNJ)$ buy the dip

03-31

Selamat Hari Raya to everyone.

03-24

Great article, would you like to share it?

Tonix Pharmaceuticals: Expects to Have Sufficient Cash to Fund Planned Operations Beyond FDA Pdufa Goal Date

03-21

$CleanSpark, Inc.(CLSK)$ fucking stocks

03-14

hoping you sold it

@LegalMaster:$JNJ 20250417 175.0 CALL$

03-10

$Faraday Future Intelligent Electric Inc.(FFAI)$ new symbol new schemes ?

03-06

$Tonix Pharmaceuticals(TNXP)$ Someone has any ideas why the stock suddenly goes up... another manipulation?

02-21

Good time to add in more

Palantir Plummeted Today -- Is It Time to Buy the Artificial Intelligence (AI) Leader's Stock

02-20

$SUPER MICRO COMPUTER INC(SMCI)$ Once the 10k filling report is produced, the stock price should go back to its original price range which is between 80-100.

02-17

thanks for the article

02-07

Hey guys, I think we still got hope. The balance sheet is now debt free. Looking good for me. $Tonix Pharmaceuticals(TNXP)$

Press Release: Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash

02-07

$CleanSpark, Inc.(CLSK)$

02-07

Solid performance from this company. As long as the shares are not diluted, we are good 💯

CleanSpark Q1 Earnings: Revenue Beat, EPS Beat, Shares Jump

02-06

Potential company ,but the management fucked up

Tonix Pharmaceuticals Announces Positive Topline Results from Phase 1 Trial for TNX-1500, a Next Generation anti-CD40L mAb Candidate for Prevention of Kidney Transplant Rejection and Treatment of Autoimmune Diseases

01-25

Wishing everyone a happy new year @Kallu and happy trading. @TigerEvents @

01-23

$Tonix Pharmaceuticals(TNXP)$

01-18

$Tonix Pharmaceuticals(TNXP)$ Underrated stock, potential to grow is there, but management fucked up. I really hope some big pharmacy would buy over this company.

01-06

No ideas bro haha

@Kallu:$CN Energy Group Inc.(CNEY)$ why it's raising @Boybabyrage @TigerGPT

Go to Tiger App to see more news

Invest in Global Markets with Tiger Brokers!

Open App

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4178332581629092","uuid":"4178332581629092","gmtCreate":1715229445250,"gmtModify":1737083335796,"name":"Boybabyrage","pinyin":"boybabyrage","introduction":"","introductionEn":"","signature":"Come here to make some coffee money 🤑","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","hat":"https://static.tigerbbs.com/50a4c8d97279fa9f8f1fa9749a6bdff4","hatId":"ca_profile_frame_feCEcj","hatName":"LV8 头像框","vip":1,"status":2,"fanSize":39,"headSize":31,"tweetSize":208,"questionSize":0,"limitLevel":999,"accountStatus":1,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":"init","userBadges":[{"badgeId":"cbe1c45c584340f3bd9ae6c77e0e9981-1","templateUuid":"cbe1c45c584340f3bd9ae6c77e0e9981","name":"Academy Experiencer","description":"5 lessons learned","bigImgUrl":"https://community-static.tradeup.com/news/fb5ae275631fb96a92d475cdc85d2302","smallImgUrl":"https://community-static.tradeup.com/news/c2660a1935bd2105e97c9915619936c3","grayImgUrl":null,"redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.10.20","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":2006},{"badgeId":"3e5a625780d3411098f7e72115f69f0a-1","templateUuid":"3e5a625780d3411098f7e72115f69f0a","name":"Total trades","description":"Cumulative for 100 trades","bigImgUrl":"https://community-static.tradeup.com/news/f6040a65e0c6e125e4dcfe0101de45ee","smallImgUrl":"https://community-static.tradeup.com/news/f803dba33fef1aa87b64be09f4f064ee","grayImgUrl":"https://community-static.tradeup.com/news/5dfa45d4a1e98a2d8c2e1b4253ddd916","redirectLinkEnabled":0,"redirectLink":"https://www.tigerbrokers.com.sg/activity/market/2023/stock-contest?adcode=StockContest2023","hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.09.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":5100},{"badgeId":"f00de38e20574ad1abf55a15966547c8-2","templateUuid":"f00de38e20574ad1abf55a15966547c8","name":"Average winning trade","description":"Top 30%","bigImgUrl":"https://community-static.tradeup.com/news/7554ebe7d1898f430d98e76f650368cf","smallImgUrl":"https://community-static.tradeup.com/news/fe4bec6a19cf99388987516558515819","grayImgUrl":"https://community-static.tradeup.com/news/18dd3e6a5c1a81de02d26eef5a5c7f28","redirectLinkEnabled":0,"redirectLink":"https://www.tigerbrokers.com.sg/activity/market/2023/stock-contest?adcode=StockContest2023","hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.08.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":5200},{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.08.23","exceedPercentage":"93.59%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.08.17","exceedPercentage":"93.35%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.05.17","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.05.11","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":7,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.05.11","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},"individualDisplayBadges":null,"crmLevel":8,"crmLevelSwitch":1,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":425138957897896,"gmtCreate":1744802521236,"gmtModify":1744809608216,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"Trump needs to be stopped&nbsp;","listText":"Trump needs to be stopped&nbsp;","text":"Trump needs to be stopped","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/425138957897896","repostId":"1130960916","repostType":2,"isVote":1,"tweetType":1,"viewCount":1,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":422120437285592,"gmtCreate":1744094193912,"gmtModify":1744094197012,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"The black tiger mug looks cool 😎","listText":"The black tiger mug looks cool 😎","text":"The black tiger mug looks cool 😎","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/422120437285592","isVote":1,"tweetType":1,"viewCount":39,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":419965148848328,"gmtCreate":1743557975059,"gmtModify":1743557977916,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/JNJ\">$Johnson &amp; Johnson(JNJ)$&nbsp;</a><v-v data-views=\"1\"></v-v> buy the dip","listText":"<a href=\"https://ttm.financial/S/JNJ\">$Johnson &amp; Johnson(JNJ)$&nbsp;</a><v-v data-views=\"1\"></v-v> buy the dip","text":"$Johnson & Johnson(JNJ)$ buy the dip","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/419965148848328","isVote":1,"tweetType":1,"viewCount":181,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":419392537108648,"gmtCreate":1743422095910,"gmtModify":1743422100426,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"Selamat Hari Raya to everyone.","listText":"Selamat Hari Raya to everyone.","text":"Selamat Hari Raya to everyone.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/419392537108648","isVote":1,"tweetType":1,"viewCount":166,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":416943192527152,"gmtCreate":1742811310962,"gmtModify":1742811314960,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/416943192527152","repostId":"2520293243","repostType":2,"repost":{"id":"2520293243","kind":"live","pubTimestamp":1742329801,"share":"https://ttm.financial/m/news/2520293243?lang=&edition=full_marsco","pubTime":"2025-03-19 04:30","market":"nz","language":"en","title":"Tonix Pharmaceuticals: Expects to Have Sufficient Cash to Fund Planned Operations Beyond FDA Pdufa Goal Date","url":"https://stock-news.laohu8.com/highlight/detail?id=2520293243","media":"THOMSON REUTERS","summary":"Tonix Pharmaceuticals: Expects to Have Sufficient Cash to Fund Planned Operations Beyond FDA Pdufa G","content":"<html><body><p>Tonix Pharmaceuticals: Expects to Have Sufficient Cash to Fund Planned Operations Beyond FDA Pdufa Goal Date</p></body></html>","source":"reuters_en_live","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tonix Pharmaceuticals: Expects to Have Sufficient Cash to Fund Planned Operations Beyond FDA Pdufa Goal Date</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTonix Pharmaceuticals: Expects to Have Sufficient Cash to Fund Planned Operations Beyond FDA Pdufa Goal Date\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-19 04:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nPLX81C8B4:4><strong>THOMSON REUTERS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tonix Pharmaceuticals: Expects to Have Sufficient Cash to Fund Planned Operations Beyond FDA Pdufa Goal Date</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nPLX81C8B4:4\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TNXP":"Tonix Pharmaceuticals Holding Co","BK4583":"猴痘概念","BK4139":"生物科技"},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nPLX81C8B4:4","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2520293243","content_text":"Tonix Pharmaceuticals: Expects to Have Sufficient Cash to Fund Planned Operations Beyond FDA Pdufa Goal Date","news_type":1},"isVote":1,"tweetType":1,"viewCount":99,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":415737945469136,"gmtCreate":1742527269491,"gmtModify":1742528114224,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/CLSK\">$CleanSpark, Inc.(CLSK)$&nbsp;</a><v-v data-views=\"0\"></v-v> fucking stocks&nbsp;","listText":"<a href=\"https://ttm.financial/S/CLSK\">$CleanSpark, Inc.(CLSK)$&nbsp;</a><v-v data-views=\"0\"></v-v> fucking stocks&nbsp;","text":"$CleanSpark, Inc.(CLSK)$ fucking stocks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/415737945469136","isVote":1,"tweetType":1,"viewCount":85,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":413426976825656,"gmtCreate":1741967111324,"gmtModify":1741967114945,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"hoping you sold it","listText":"hoping you sold it","text":"hoping you sold it","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/413426976825656","repostId":"410092213248072","repostType":1,"repost":{"id":410092213248072,"gmtCreate":1741099665597,"gmtModify":1741102476842,"author":{"id":"3575537732332106","authorId":"3575537732332106","name":"LegalMaster","avatar":"https://static.tigerbbs.com/fa128ffaebc77e7d5363f158ef90b2d4","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3575537732332106","authorIdStr":"3575537732332106"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/OPT/JNJ 20250417 175.0 CALL\">$JNJ 20250417 175.0 CALL$</a>&nbsp;","listText":"<a href=\"https://ttm.financial/OPT/JNJ 20250417 175.0 CALL\">$JNJ 20250417 175.0 CALL$</a>&nbsp;","text":"$JNJ 20250417 175.0 CALL$","images":[{"img":"https://community-static.tradeup.com/news/557cdf80c430f40d2f40f84fb50009bb","width":"1086","height":"1713"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/410092213248072","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":229,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":412289012416608,"gmtCreate":1741624939248,"gmtModify":1741624943750,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/FFAI\">$Faraday Future Intelligent Electric Inc.(FFAI)$ </a> new symbol new schemes ?","listText":"<a href=\"https://ttm.financial/S/FFAI\">$Faraday Future Intelligent Electric Inc.(FFAI)$ </a> new symbol new schemes ?","text":"$Faraday Future Intelligent Electric Inc.(FFAI)$ new symbol new schemes ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/412289012416608","isVote":1,"tweetType":1,"viewCount":285,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":410630392594784,"gmtCreate":1741277520410,"gmtModify":1741277523662,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a> Someone has any ideas why the stock suddenly goes up... another manipulation?&nbsp;","listText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a> Someone has any ideas why the stock suddenly goes up... another manipulation?&nbsp;","text":"$Tonix Pharmaceuticals(TNXP)$ Someone has any ideas why the stock suddenly goes up... another manipulation?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":1,"link":"https://ttm.financial/post/410630392594784","isVote":1,"tweetType":1,"viewCount":444,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"content":"The investor summit is currently $Tonix Pharmaceuticals(TNXP)$ happening. It might be a good opportunity to secure some funding.","text":"The investor summit is currently $Tonix Pharmaceuticals(TNXP)$ happening. It might be a good opportunity to secure some funding.","html":"The investor summit is currently $Tonix Pharmaceuticals(TNXP)$ happening. It might be a good opportunity to secure some funding."}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":405943833358456,"gmtCreate":1740135181383,"gmtModify":1740143994595,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"Good time to add in more&nbsp;","listText":"Good time to add in more&nbsp;","text":"Good time to add in more","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/405943833358456","repostId":"2512430749","repostType":2,"repost":{"id":"2512430749","kind":"highlight","pubTimestamp":1739999160,"share":"https://ttm.financial/m/news/2512430749?lang=&edition=full_marsco","pubTime":"2025-02-20 05:06","market":"us","language":"en","title":"Palantir Plummeted Today -- Is It Time to Buy the Artificial Intelligence (AI) Leader's Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2512430749","media":"Motley Fool","summary":"Palantir saw a pullback early in today's trading in conjunction with CEO Alex Karp's plan to sell $1.2 billion in company stock.Palantir  stock saw big sell-offs in Wednesday's trading. The software specialist's share price ended the daily session down 10.1% and had been off as much as 12.9% earlier in trading.Palantir stock saw a pullback early in today's trading following a disclosure yesterday that CEO Alex Karp plans to sell $1.2 billion in company stock. Sell-offs intensified late in the day's trading following a report from The Washington Post that suggested big defense spending cuts could be on the horizon. According to the report, Defense Secretary Pete Hegseth has instructed Pentagon officials to prepare for budget cuts that could come in as high as 8% annually over the next five years. With Karp laying the groundwork to move forward with a new stock-selling plan and the potential for Palantir to see weaker public-sector demand, investors got multiple bearish signals today. Bu","content":"<html><body><ul>\n<li>\n<div>\n<svg fill=\"none\" height=\"15\" viewbox=\"0 0 14 15\" width=\"14\" xmlns=\"http://www.w3.org/2000/svg\">\n<path d=\"M14 5.58984C14 2.91016 11.8398 0.75 9.16016 0.75C6.50781 0.777344 4.375 2.91016 4.375 5.5625C4.375 6.10938 4.45703 6.60156 4.59375 7.09375L0.191406 11.4961C0.0546875 11.6328 0 11.7969 0 11.9609V14.0938C0 14.4766 0.273438 14.75 0.65625 14.75H3.71875C4.07422 14.75 4.375 14.4766 4.375 14.0938V13H5.46875C5.82422 13 6.125 12.7266 6.125 12.3438V11.25H7.13672C7.30078 11.25 7.51953 11.168 7.62891 11.0312L8.28516 10.293C8.55859 10.3477 8.85938 10.375 9.1875 10.375C11.8398 10.375 14 8.24219 14 5.58984ZM9.1875 4.25C9.1875 3.53906 9.76172 2.9375 10.5 2.9375C11.2109 2.9375 11.8125 3.53906 11.8125 4.25C11.8125 4.98828 11.2109 5.5625 10.5 5.5625C9.76172 5.5625 9.1875 4.98828 9.1875 4.25Z\" fill=\"#FFB81C\"></path>\n</svg>\n</div>\n<div>Palantir saw a pullback early in today's trading in conjunction with CEO Alex Karp's plan to sell $1.2 billion in company stock. </div>\n</li>\n<li>\n<div>\n<svg fill=\"none\" height=\"15\" viewbox=\"0 0 14 15\" width=\"14\" xmlns=\"http://www.w3.org/2000/svg\">\n<path d=\"M14 5.58984C14 2.91016 11.8398 0.75 9.16016 0.75C6.50781 0.777344 4.375 2.91016 4.375 5.5625C4.375 6.10938 4.45703 6.60156 4.59375 7.09375L0.191406 11.4961C0.0546875 11.6328 0 11.7969 0 11.9609V14.0938C0 14.4766 0.273438 14.75 0.65625 14.75H3.71875C4.07422 14.75 4.375 14.4766 4.375 14.0938V13H5.46875C5.82422 13 6.125 12.7266 6.125 12.3438V11.25H7.13672C7.30078 11.25 7.51953 11.168 7.62891 11.0312L8.28516 10.293C8.55859 10.3477 8.85938 10.375 9.1875 10.375C11.8398 10.375 14 8.24219 14 5.58984ZM9.1875 4.25C9.1875 3.53906 9.76172 2.9375 10.5 2.9375C11.2109 2.9375 11.8125 3.53906 11.8125 4.25C11.8125 4.98828 11.2109 5.5625 10.5 5.5625C9.76172 5.5625 9.1875 4.98828 9.1875 4.25Z\" fill=\"#FFB81C\"></path>\n</svg>\n</div>\n<div>The stock saw much bigger sell-offs later in the day following a report that suggests that the U.S. defense budget could see major cuts.  </div>\n</li>\n<li>\n<div>\n<svg fill=\"none\" height=\"15\" viewbox=\"0 0 14 15\" width=\"14\" xmlns=\"http://www.w3.org/2000/svg\">\n<path d=\"M14 5.58984C14 2.91016 11.8398 0.75 9.16016 0.75C6.50781 0.777344 4.375 2.91016 4.375 5.5625C4.375 6.10938 4.45703 6.60156 4.59375 7.09375L0.191406 11.4961C0.0546875 11.6328 0 11.7969 0 11.9609V14.0938C0 14.4766 0.273438 14.75 0.65625 14.75H3.71875C4.07422 14.75 4.375 14.4766 4.375 14.0938V13H5.46875C5.82422 13 6.125 12.7266 6.125 12.3438V11.25H7.13672C7.30078 11.25 7.51953 11.168 7.62891 11.0312L8.28516 10.293C8.55859 10.3477 8.85938 10.375 9.1875 10.375C11.8398 10.375 14 8.24219 14 5.58984ZM9.1875 4.25C9.1875 3.53906 9.76172 2.9375 10.5 2.9375C11.2109 2.9375 11.8125 3.53906 11.8125 4.25C11.8125 4.98828 11.2109 5.5625 10.5 5.5625C9.76172 5.5625 9.1875 4.98828 9.1875 4.25Z\" fill=\"#FFB81C\"></path>\n</svg>\n</div>\n<div>Palantir's growth-dependent valuation makes it a risky stock, but buying on pullbacks could prove very rewarding for long-term investors. </div>\n</li>\n</ul><div><p><strong>Palantir</strong> <span>(PLTR<span> -10.08%</span>)</span> stock saw big sell-offs in Wednesday's trading. The software specialist's share price ended the daily session down 10.1% and had been off as much as 12.9% earlier in trading.</p><div><app :collapse_on_load=\"false\" :instrument_id=\"343121\" :show_benchmark_compare=\"false\" amount_change=\"-12.56\" average_volume=\"83,737,678\" company_name=\"Palantir Technologies\" current_price=\"112.06\" daily_high=\"125.41\" daily_low=\"108.56\" default_period=\"OneWeek\" dividend_yield=\"N/A\" exchange=\"NASDAQ\" fifty_two_week_high=\"125.41\" fifty_two_week_low=\"20.33\" gross_margin=\"80.25\" logo=\"https://g.foolcdn.com/art/companylogos/mark/PLTR.png\" market_cap=\"$284B\" pe_ratio=\"663.23\" percent_change=\"-10.08\" symbol=\"PLTR\" volume=\"137,947,754\"></app></div><p>Palantir stock saw a pullback early in today's trading following a disclosure yesterday that CEO Alex Karp plans to sell $1.2 billion in company stock. Sell-offs intensified late in the day's trading following a report from <em>The Washington Post</em> that suggested big defense spending cuts could be on the horizon. According to the report, Defense Secretary Pete Hegseth has instructed Pentagon officials to prepare for budget cuts that could come in as high as 8% annually over the next five years. </p><p>With Karp laying the groundwork to move forward with a new stock-selling plan and the potential for Palantir to see weaker public-sector demand, investors got multiple bearish signals today. But even with the substantial valuation retreat, Palantir stock is still up roughly 360% over the last year.</p><h2>Is Palantir stock a buy right now?</h2><p>Even with today's double-digit share price pullback, Palantir is still valued at roughly 203 times this year's expected earnings and 68 times this year's expected sales. With such a highly growth-dependent valuation, the stock probably isn't a good portfolio addition for risk-averse investors or those without tolerance for high levels of volatility in the near term. </p><p>And while Palantir's heavily forward-looking valuation opens the door for the stock to see big swings even on relatively little news, significant cuts for the U.S. defense budget could result in a material worsening for the company's operating backdrop. On the other hand, it's possible that an elevated focus on efficiency within Department of Defense (DOD) would actually create some positive demand catalysts for Palantir. For starters, there's a fair chance that the company's software will be used to identify the best areas to reduce spending. The company's artificial intelligence (AI) software tools could also be used to automate tasks at the Pentagon.</p><div><div><div></div></div></div><p>Despite reports of possible DOD budget cuts, I think that Palantir's outlook in the defense industry remains very strong. While the company's growth-dependent valuation comes with a high level of risk, I expect that investors who buy shares at today's prices and hold over a five-year period will see very strong returns -- even if there's a lot of volatility in between.</p><div></div></div></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir Plummeted Today -- Is It Time to Buy the Artificial Intelligence (AI) Leader's Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir Plummeted Today -- Is It Time to Buy the Artificial Intelligence (AI) Leader's Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-02-20 05:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2025/02/19/palantir-plummeted-today-is-it-time-to-buy-the-art/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir saw a pullback early in today's trading in conjunction with CEO Alex Karp's plan to sell $1.2 billion in company stock. \n\n\n\n\n\n\n\nThe stock saw much bigger sell-offs later in the day following ...</p>\n\n<a href=\"https://www.fool.com/investing/2025/02/19/palantir-plummeted-today-is-it-time-to-buy-the-art/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4551":"寇图资本持仓","BK4585":"ETF&股票定投概念","AI":"C3.ai, Inc.","BK4547":"WSB热门概念","BK4543":"AI","IE00B29SXL02.USD":"FIRST SENTIER GLOBAL LISTED INFRASTRUCTURE \"I\" (USD) INC","BK4588":"碎股","BK4528":"SaaS概念","BK4023":"应用软件","BK4587":"ChatGPT概念","IE00B29SXK94.USD":"FIRST SENTIER GLOBAL LISTED INFRASTRUCTURE \"I\" (USD) ACC","LU1861558580.USD":"日兴方舟颠覆性创新基金B","DOD":"Elements ETN-Dow Jones High Yiel","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD"},"source_url":"https://www.fool.com/investing/2025/02/19/palantir-plummeted-today-is-it-time-to-buy-the-art/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2512430749","content_text":"Palantir saw a pullback early in today's trading in conjunction with CEO Alex Karp's plan to sell $1.2 billion in company stock. \n\n\n\n\n\n\n\nThe stock saw much bigger sell-offs later in the day following a report that suggests that the U.S. defense budget could see major cuts.  \n\n\n\n\n\n\n\nPalantir's growth-dependent valuation makes it a risky stock, but buying on pullbacks could prove very rewarding for long-term investors. \n\nPalantir (PLTR -10.08%) stock saw big sell-offs in Wednesday's trading. The software specialist's share price ended the daily session down 10.1% and had been off as much as 12.9% earlier in trading.Palantir stock saw a pullback early in today's trading following a disclosure yesterday that CEO Alex Karp plans to sell $1.2 billion in company stock. Sell-offs intensified late in the day's trading following a report from The Washington Post that suggested big defense spending cuts could be on the horizon. According to the report, Defense Secretary Pete Hegseth has instructed Pentagon officials to prepare for budget cuts that could come in as high as 8% annually over the next five years. With Karp laying the groundwork to move forward with a new stock-selling plan and the potential for Palantir to see weaker public-sector demand, investors got multiple bearish signals today. But even with the substantial valuation retreat, Palantir stock is still up roughly 360% over the last year.Is Palantir stock a buy right now?Even with today's double-digit share price pullback, Palantir is still valued at roughly 203 times this year's expected earnings and 68 times this year's expected sales. With such a highly growth-dependent valuation, the stock probably isn't a good portfolio addition for risk-averse investors or those without tolerance for high levels of volatility in the near term. And while Palantir's heavily forward-looking valuation opens the door for the stock to see big swings even on relatively little news, significant cuts for the U.S. defense budget could result in a material worsening for the company's operating backdrop. On the other hand, it's possible that an elevated focus on efficiency within Department of Defense (DOD) would actually create some positive demand catalysts for Palantir. For starters, there's a fair chance that the company's software will be used to identify the best areas to reduce spending. The company's artificial intelligence (AI) software tools could also be used to automate tasks at the Pentagon.Despite reports of possible DOD budget cuts, I think that Palantir's outlook in the defense industry remains very strong. While the company's growth-dependent valuation comes with a high level of risk, I expect that investors who buy shares at today's prices and hold over a five-year period will see very strong returns -- even if there's a lot of volatility in between.","news_type":1},"isVote":1,"tweetType":1,"viewCount":367,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":405424627691856,"gmtCreate":1740019558261,"gmtModify":1740019562276,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/SMCI\">$SUPER MICRO COMPUTER INC(SMCI)$&nbsp;</a><v-v data-views=\"1\"></v-v> Once the 10k filling report is produced, the stock price should go back to its original price range which is between 80-100.&nbsp;","listText":"<a href=\"https://ttm.financial/S/SMCI\">$SUPER MICRO COMPUTER INC(SMCI)$&nbsp;</a><v-v data-views=\"1\"></v-v> Once the 10k filling report is produced, the stock price should go back to its original price range which is between 80-100.&nbsp;","text":"$SUPER MICRO COMPUTER INC(SMCI)$ Once the 10k filling report is produced, the stock price should go back to its original price range which is between 80-100.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/405424627691856","isVote":1,"tweetType":1,"viewCount":810,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":404613098115368,"gmtCreate":1739806479678,"gmtModify":1739806483489,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"thanks for the article","listText":"thanks for the article","text":"thanks for the article","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/404613098115368","isVote":1,"tweetType":1,"viewCount":453,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":401039356875440,"gmtCreate":1738937595203,"gmtModify":1738937598596,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"Hey guys, I think we still got hope. The balance sheet is now debt free. Looking good for me.&nbsp;&nbsp;<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","listText":"Hey guys, I think we still got hope. The balance sheet is now debt free. Looking good for me.&nbsp;&nbsp;<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","text":"Hey guys, I think we still got hope. The balance sheet is now debt free. Looking good for me. $Tonix Pharmaceuticals(TNXP)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/401039356875440","repostId":"2509745172","repostType":2,"repost":{"id":"2509745172","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1738935000,"share":"https://ttm.financial/m/news/2509745172?lang=&edition=full_marsco","pubTime":"2025-02-07 21:30","market":"sh","language":"en","title":"Press Release: Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash","url":"https://stock-news.laohu8.com/highlight/detail?id=2509745172","media":"Dow Jones","summary":"Company had $98.8 million in cash as of December 31, 2024; existing cash expected to fund planned operations into the first quarter of 2026. Company is debt-free after repaying mortgage on facilities. TNX-102 SL fibromyalgia FDA PDUFA goal date is August 15, 2025. $10.1 million in net sales from migraine products in 2024. CHATHAM, N.J., Feb. 07, 2025  -- Tonix Pharmaceuticals Holding Corp.  , a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, recently announced selected preliminary operating results for the year ended December 31, 2024, and certain preliminary financial condition information as of December 31, 2024. The above information is preliminary financial information for the year ended December 31, 2024 and subject to completion. The unaudited, estimated results for the year ended December 31, 2024 are preliminary and were prepared by the Company's management, based upon its estimates, a number of assumptions and current","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     Zembrace and Tosymra can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop use and get emergency help if you have any signs of a heart attack: \n</p>\n<pre>\n   -- discomfort in the center of your chest that lasts for more than a few \n      minutes or goes away and comes back \n \n   -- severe tightness, pain, pressure, or heaviness in your chest, throat, \n      neck, or jaw \n \n   -- pain or discomfort in your arms, back, neck, jaw or stomach \n \n   -- shortness of breath with or without chest discomfort \n \n   -- breaking out in a cold sweat \n \n   -- nausea or vomiting \n \n   -- feeling lightheaded \n</pre>\n<p>\n     Zembrace and Tosymra are not for people with risk factors for heart disease (high blood pressure or cholesterol, smoking, overweight, diabetes, family history of heart disease) unless a heart exam shows no problem. \n</p>\n<p>\n     Do not use Zembrace or Tosymra if you have: \n</p>\n<pre>\n   -- history of heart problems \n \n   -- narrowing of blood vessels to your legs, arms, stomach, or kidney \n      (peripheral vascular disease) \n \n   -- uncontrolled high blood pressure \n \n   -- hemiplegic or basilar migraines. If you are not sure if you have these, \n      ask your provider. \n \n   -- had a stroke, transient ischemic attacks (TIAs), or problems with blood \n      circulation \n \n   -- severe liver problems \n \n   -- taken any of the following medicines in the last 24 hours: almotriptan, \n      eletriptan, frovatriptan, naratriptan, rizatriptan, ergotamines, or \n      dihydroergotamine. Ask your provider for a list of these medicines if you \n      are not sure. \n \n   -- are taking certain antidepressants, known as monoamine oxidase (MAO)-A \n      inhibitors or it has been 2 weeks or less since you stopped taking a \n      MAO-A inhibitor. Ask your provider for a list of these medicines if you \n      are not sure. \n \n   -- an allergy to sumatriptan or any of the components of Zembrace or Tosymra \n</pre>\n<p>\n     Tell your provider about all of your medical conditions and medicines you take, including vitamins and supplements. \n</p>\n<p>\n     Zembrace and Tosymra can cause dizziness, weakness, or drowsiness. If so, do not drive a car, use machinery, or do anything where you need to be alert. \n</p>\n<p>\n     Zembrace and Tosymra may cause serious side effects including: \n</p>\n<pre>\n   -- changes in color or sensation in your fingers and toes \n \n   -- sudden or severe stomach pain, stomach pain after meals, weight loss, \n      nausea or vomiting, constipation or diarrhea, bloody diarrhea, fever \n \n   -- cramping and pain in your legs or hips; feeling of heaviness or tightness \n      in your leg muscles; burning or aching pain in your feet or toes while \n      resting; numbness, tingling, or weakness in your legs; cold feeling or \n      color changes in one or both legs or feet \n \n   -- increased blood pressure including a sudden severe increase even if you \n      have no history of high blood pressure \n \n   -- medication overuse headaches from using migraine medicine for 10 or more \n      days each month. If your headaches get worse, call your provider. \n \n   -- serotonin syndrome, a rare but serious problem that can happen in people \n      using Zembrace or Tosymra, especially when used with anti-depressant \n      medicines called SSRIs or SNRIs. Call your provider right away if you \n      have: mental changes such as seeing things that are not there \n      (hallucinations), agitation, or coma; fast heartbeat; changes in blood \n      pressure; high body temperature; tight muscles; or trouble walking. \n \n   -- hives (itchy bumps); swelling of your tongue, mouth, or throat \n \n   -- seizures even in people who have never had seizures before \n</pre>\n<p>\n     The most common side effects of Zembrace and Tosymra include: pain and redness at injection site (Zembrace only); tingling or numbness in your fingers or toes; dizziness; warm, hot, burning feeling to your face (flushing); discomfort or stiffness in your neck; feeling weak, drowsy, or tired; application site (nasal) reactions (Tosymra only) and throat irritation (Tosymra only). \n</p>\n<p>\n     Tell your provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of Zembrace and Tosymra. For more information, ask your provider. \n</p>\n<p>\n     This is the most important information to know about Zembrace and Tosymra but is not comprehensive. For more information, talk to your provider and read the Patient Information and Instructions for Use. You can also visit https://www.tonixpharma.com or call 1-888-869-7633. \n</p>\n<p>\n     You are encouraged to report adverse effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 07, 2025 08:30 ET (13:30 GMT)\n</p>\n</font>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Press Release: Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPress Release: Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-02-07 21:30</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     Zembrace and Tosymra can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop use and get emergency help if you have any signs of a heart attack: \n</p>\n<pre>\n   -- discomfort in the center of your chest that lasts for more than a few \n      minutes or goes away and comes back \n \n   -- severe tightness, pain, pressure, or heaviness in your chest, throat, \n      neck, or jaw \n \n   -- pain or discomfort in your arms, back, neck, jaw or stomach \n \n   -- shortness of breath with or without chest discomfort \n \n   -- breaking out in a cold sweat \n \n   -- nausea or vomiting \n \n   -- feeling lightheaded \n</pre>\n<p>\n     Zembrace and Tosymra are not for people with risk factors for heart disease (high blood pressure or cholesterol, smoking, overweight, diabetes, family history of heart disease) unless a heart exam shows no problem. \n</p>\n<p>\n     Do not use Zembrace or Tosymra if you have: \n</p>\n<pre>\n   -- history of heart problems \n \n   -- narrowing of blood vessels to your legs, arms, stomach, or kidney \n      (peripheral vascular disease) \n \n   -- uncontrolled high blood pressure \n \n   -- hemiplegic or basilar migraines. If you are not sure if you have these, \n      ask your provider. \n \n   -- had a stroke, transient ischemic attacks (TIAs), or problems with blood \n      circulation \n \n   -- severe liver problems \n \n   -- taken any of the following medicines in the last 24 hours: almotriptan, \n      eletriptan, frovatriptan, naratriptan, rizatriptan, ergotamines, or \n      dihydroergotamine. Ask your provider for a list of these medicines if you \n      are not sure. \n \n   -- are taking certain antidepressants, known as monoamine oxidase (MAO)-A \n      inhibitors or it has been 2 weeks or less since you stopped taking a \n      MAO-A inhibitor. Ask your provider for a list of these medicines if you \n      are not sure. \n \n   -- an allergy to sumatriptan or any of the components of Zembrace or Tosymra \n</pre>\n<p>\n     Tell your provider about all of your medical conditions and medicines you take, including vitamins and supplements. \n</p>\n<p>\n     Zembrace and Tosymra can cause dizziness, weakness, or drowsiness. If so, do not drive a car, use machinery, or do anything where you need to be alert. \n</p>\n<p>\n     Zembrace and Tosymra may cause serious side effects including: \n</p>\n<pre>\n   -- changes in color or sensation in your fingers and toes \n \n   -- sudden or severe stomach pain, stomach pain after meals, weight loss, \n      nausea or vomiting, constipation or diarrhea, bloody diarrhea, fever \n \n   -- cramping and pain in your legs or hips; feeling of heaviness or tightness \n      in your leg muscles; burning or aching pain in your feet or toes while \n      resting; numbness, tingling, or weakness in your legs; cold feeling or \n      color changes in one or both legs or feet \n \n   -- increased blood pressure including a sudden severe increase even if you \n      have no history of high blood pressure \n \n   -- medication overuse headaches from using migraine medicine for 10 or more \n      days each month. If your headaches get worse, call your provider. \n \n   -- serotonin syndrome, a rare but serious problem that can happen in people \n      using Zembrace or Tosymra, especially when used with anti-depressant \n      medicines called SSRIs or SNRIs. Call your provider right away if you \n      have: mental changes such as seeing things that are not there \n      (hallucinations), agitation, or coma; fast heartbeat; changes in blood \n      pressure; high body temperature; tight muscles; or trouble walking. \n \n   -- hives (itchy bumps); swelling of your tongue, mouth, or throat \n \n   -- seizures even in people who have never had seizures before \n</pre>\n<p>\n     The most common side effects of Zembrace and Tosymra include: pain and redness at injection site (Zembrace only); tingling or numbness in your fingers or toes; dizziness; warm, hot, burning feeling to your face (flushing); discomfort or stiffness in your neck; feeling weak, drowsy, or tired; application site (nasal) reactions (Tosymra only) and throat irritation (Tosymra only). \n</p>\n<p>\n     Tell your provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of Zembrace and Tosymra. For more information, ask your provider. \n</p>\n<p>\n     This is the most important information to know about Zembrace and Tosymra but is not comprehensive. For more information, talk to your provider and read the Patient Information and Instructions for Use. You can also visit https://www.tonixpharma.com or call 1-888-869-7633. \n</p>\n<p>\n     You are encouraged to report adverse effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 07, 2025 08:30 ET (13:30 GMT)\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TNXP":"Tonix Pharmaceuticals Holding Co"},"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2509745172","content_text":"Zembrace and Tosymra can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop use and get emergency help if you have any signs of a heart attack: \n\n\n   -- discomfort in the center of your chest that lasts for more than a few \n      minutes or goes away and comes back \n \n   -- severe tightness, pain, pressure, or heaviness in your chest, throat, \n      neck, or jaw \n \n   -- pain or discomfort in your arms, back, neck, jaw or stomach \n \n   -- shortness of breath with or without chest discomfort \n \n   -- breaking out in a cold sweat \n \n   -- nausea or vomiting \n \n   -- feeling lightheaded \n\n\n     Zembrace and Tosymra are not for people with risk factors for heart disease (high blood pressure or cholesterol, smoking, overweight, diabetes, family history of heart disease) unless a heart exam shows no problem. \n\n\n     Do not use Zembrace or Tosymra if you have: \n\n\n   -- history of heart problems \n \n   -- narrowing of blood vessels to your legs, arms, stomach, or kidney \n      (peripheral vascular disease) \n \n   -- uncontrolled high blood pressure \n \n   -- hemiplegic or basilar migraines. If you are not sure if you have these, \n      ask your provider. \n \n   -- had a stroke, transient ischemic attacks (TIAs), or problems with blood \n      circulation \n \n   -- severe liver problems \n \n   -- taken any of the following medicines in the last 24 hours: almotriptan, \n      eletriptan, frovatriptan, naratriptan, rizatriptan, ergotamines, or \n      dihydroergotamine. Ask your provider for a list of these medicines if you \n      are not sure. \n \n   -- are taking certain antidepressants, known as monoamine oxidase (MAO)-A \n      inhibitors or it has been 2 weeks or less since you stopped taking a \n      MAO-A inhibitor. Ask your provider for a list of these medicines if you \n      are not sure. \n \n   -- an allergy to sumatriptan or any of the components of Zembrace or Tosymra \n\n\n     Tell your provider about all of your medical conditions and medicines you take, including vitamins and supplements. \n\n\n     Zembrace and Tosymra can cause dizziness, weakness, or drowsiness. If so, do not drive a car, use machinery, or do anything where you need to be alert. \n\n\n     Zembrace and Tosymra may cause serious side effects including: \n\n\n   -- changes in color or sensation in your fingers and toes \n \n   -- sudden or severe stomach pain, stomach pain after meals, weight loss, \n      nausea or vomiting, constipation or diarrhea, bloody diarrhea, fever \n \n   -- cramping and pain in your legs or hips; feeling of heaviness or tightness \n      in your leg muscles; burning or aching pain in your feet or toes while \n      resting; numbness, tingling, or weakness in your legs; cold feeling or \n      color changes in one or both legs or feet \n \n   -- increased blood pressure including a sudden severe increase even if you \n      have no history of high blood pressure \n \n   -- medication overuse headaches from using migraine medicine for 10 or more \n      days each month. If your headaches get worse, call your provider. \n \n   -- serotonin syndrome, a rare but serious problem that can happen in people \n      using Zembrace or Tosymra, especially when used with anti-depressant \n      medicines called SSRIs or SNRIs. Call your provider right away if you \n      have: mental changes such as seeing things that are not there \n      (hallucinations), agitation, or coma; fast heartbeat; changes in blood \n      pressure; high body temperature; tight muscles; or trouble walking. \n \n   -- hives (itchy bumps); swelling of your tongue, mouth, or throat \n \n   -- seizures even in people who have never had seizures before \n\n\n     The most common side effects of Zembrace and Tosymra include: pain and redness at injection site (Zembrace only); tingling or numbness in your fingers or toes; dizziness; warm, hot, burning feeling to your face (flushing); discomfort or stiffness in your neck; feeling weak, drowsy, or tired; application site (nasal) reactions (Tosymra only) and throat irritation (Tosymra only). \n\n\n     Tell your provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of Zembrace and Tosymra. For more information, ask your provider. \n\n\n     This is the most important information to know about Zembrace and Tosymra but is not comprehensive. For more information, talk to your provider and read the Patient Information and Instructions for Use. You can also visit https://www.tonixpharma.com or call 1-888-869-7633. \n\n\n     You are encouraged to report adverse effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. \n\n\n  (END) Dow Jones Newswires\n\n\n  February 07, 2025 08:30 ET (13:30 GMT)","news_type":1},"isVote":1,"tweetType":1,"viewCount":871,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":400991303983464,"gmtCreate":1738905983412,"gmtModify":1738905987314,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/CLSK\">$CleanSpark, Inc.(CLSK)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","listText":"<a href=\"https://ttm.financial/S/CLSK\">$CleanSpark, Inc.(CLSK)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","text":"$CleanSpark, Inc.(CLSK)$","images":[{"img":"https://community-static.tradeup.com/news/d0d37d2e63932b53b375bbe50b9f72fb","width":"1008","height":"1500"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/400991303983464","isVote":1,"tweetType":1,"viewCount":413,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":400991133425904,"gmtCreate":1738905931648,"gmtModify":1738905935726,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"Solid performance from this company. As long as the shares are not diluted, we are good 💯&nbsp;","listText":"Solid performance from this company. As long as the shares are not diluted, we are good 💯&nbsp;","text":"Solid performance from this company. As long as the shares are not diluted, we are good 💯","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/400991133425904","repostId":"2509782734","repostType":2,"repost":{"id":"2509782734","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1738893316,"share":"https://ttm.financial/m/news/2509782734?lang=&edition=full_marsco","pubTime":"2025-02-07 09:55","market":"us","language":"en","title":"CleanSpark Q1 Earnings: Revenue Beat, EPS Beat, Shares Jump","url":"https://stock-news.laohu8.com/highlight/detail?id=2509782734","media":"Benzinga","summary":"CleanSpark Inc reported first-quarter financial results after the market close on Thursday. Here’s a rundown of the report.Q1 Earnings: CleanSpark reported first-quarter revenue of $162.3 million, bea","content":"<html><head></head><body><p style=\"text-align: start;\"><strong>CleanSpark Inc</strong> reported first-quarter financial results after the market close on Thursday. Here’s a rundown of the report.</p><p style=\"text-align: start;\"><strong>Q1 Earnings:</strong> CleanSpark reported first-quarter revenue of $162.3 million, beating analyst estimates of $150.87 million, according to Benzinga Pro. The <strong>Bitcoin</strong> miner reported earnings of 85 cents per share, beating analyst estimates of 9 cents per share.</p><p style=\"text-align: start;\">Total revenue was up 120% on a year-over-year basis. Adjusted EBITDA came in at $321.6 million, up from $69.1 million in the prior year’s quarter. CleanSpark said it ended the quarter with $929.1 million in Bitcoin and $276.6 million in cash. The company had working capital of $1.2 billion as of Dec. 31.</p><p>CleanSpark shares jumped 6% in overnight trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/2a057cdd5ad66c9a3ab980d709744ac5\" tg-width=\"855\" tg-height=\"625\"/></p><p style=\"text-align: start;\">“This quarter we saw the impact of continuous improvements across what we believe to be the most important industry metrics: operating hashrate, fleet efficiency, marginal cost to mine, bitcoin treasury, and portfolio uptime,” said <strong>Zach Bradford</strong>, CEO of CleanSpark.</p><p style=\"text-align: start;\">“We exceeded 2024 guidance and surpassed 40 EH/s in January, while driving fleet efficiency down to 16.15 J/Th. “CleanSpark delivered $162.3 million in revenue at a marginal cost to mine of approximately $34,000 per bitcoin for the quarter.”</p><p style=\"text-align: start;\">CleanSpark’s Bitcoin holdings grew to over 10,500 in the quarter. The company noted that all of its Bitcoin has been self-mined.</p><p style=\"text-align: start;\">CleanSpark CFO <strong>Gary Vecchiarelli</strong> said, “We continue to invest in ourselves because why buy Bitcoin at current spot prices when we can mine it for $34,000?”</p><p>CleanSpark noted that its hashrate surpassed 40 EH/s in January. The company expects to reach its goal of 50 EH/s in the first half of 2025.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CleanSpark Q1 Earnings: Revenue Beat, EPS Beat, Shares Jump</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCleanSpark Q1 Earnings: Revenue Beat, EPS Beat, Shares Jump\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2025-02-07 09:55</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p style=\"text-align: start;\"><strong>CleanSpark Inc</strong> reported first-quarter financial results after the market close on Thursday. Here’s a rundown of the report.</p><p style=\"text-align: start;\"><strong>Q1 Earnings:</strong> CleanSpark reported first-quarter revenue of $162.3 million, beating analyst estimates of $150.87 million, according to Benzinga Pro. The <strong>Bitcoin</strong> miner reported earnings of 85 cents per share, beating analyst estimates of 9 cents per share.</p><p style=\"text-align: start;\">Total revenue was up 120% on a year-over-year basis. Adjusted EBITDA came in at $321.6 million, up from $69.1 million in the prior year’s quarter. CleanSpark said it ended the quarter with $929.1 million in Bitcoin and $276.6 million in cash. The company had working capital of $1.2 billion as of Dec. 31.</p><p>CleanSpark shares jumped 6% in overnight trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/2a057cdd5ad66c9a3ab980d709744ac5\" tg-width=\"855\" tg-height=\"625\"/></p><p style=\"text-align: start;\">“This quarter we saw the impact of continuous improvements across what we believe to be the most important industry metrics: operating hashrate, fleet efficiency, marginal cost to mine, bitcoin treasury, and portfolio uptime,” said <strong>Zach Bradford</strong>, CEO of CleanSpark.</p><p style=\"text-align: start;\">“We exceeded 2024 guidance and surpassed 40 EH/s in January, while driving fleet efficiency down to 16.15 J/Th. “CleanSpark delivered $162.3 million in revenue at a marginal cost to mine of approximately $34,000 per bitcoin for the quarter.”</p><p style=\"text-align: start;\">CleanSpark’s Bitcoin holdings grew to over 10,500 in the quarter. The company noted that all of its Bitcoin has been self-mined.</p><p style=\"text-align: start;\">CleanSpark CFO <strong>Gary Vecchiarelli</strong> said, “We continue to invest in ourselves because why buy Bitcoin at current spot prices when we can mine it for $34,000?”</p><p>CleanSpark noted that its hashrate surpassed 40 EH/s in January. The company expects to reach its goal of 50 EH/s in the first half of 2025.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLSK":"CleanSpark, Inc."},"source_url":"https://www.benzinga.com/news/earnings/25/02/43547080/cleanspark-q1-earnings-revenue-beat-eps-beat-shares-jump-why-buy-bitcoin-at-current-spot-prices-when-we-can-mine-it-for-34000","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2509782734","content_text":"CleanSpark Inc reported first-quarter financial results after the market close on Thursday. Here’s a rundown of the report.Q1 Earnings: CleanSpark reported first-quarter revenue of $162.3 million, beating analyst estimates of $150.87 million, according to Benzinga Pro. The Bitcoin miner reported earnings of 85 cents per share, beating analyst estimates of 9 cents per share.Total revenue was up 120% on a year-over-year basis. Adjusted EBITDA came in at $321.6 million, up from $69.1 million in the prior year’s quarter. CleanSpark said it ended the quarter with $929.1 million in Bitcoin and $276.6 million in cash. The company had working capital of $1.2 billion as of Dec. 31.CleanSpark shares jumped 6% in overnight trading.“This quarter we saw the impact of continuous improvements across what we believe to be the most important industry metrics: operating hashrate, fleet efficiency, marginal cost to mine, bitcoin treasury, and portfolio uptime,” said Zach Bradford, CEO of CleanSpark.“We exceeded 2024 guidance and surpassed 40 EH/s in January, while driving fleet efficiency down to 16.15 J/Th. “CleanSpark delivered $162.3 million in revenue at a marginal cost to mine of approximately $34,000 per bitcoin for the quarter.”CleanSpark’s Bitcoin holdings grew to over 10,500 in the quarter. The company noted that all of its Bitcoin has been self-mined.CleanSpark CFO Gary Vecchiarelli said, “We continue to invest in ourselves because why buy Bitcoin at current spot prices when we can mine it for $34,000?”CleanSpark noted that its hashrate surpassed 40 EH/s in January. The company expects to reach its goal of 50 EH/s in the first half of 2025.","news_type":1},"isVote":1,"tweetType":1,"viewCount":687,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":400763440226984,"gmtCreate":1738849970645,"gmtModify":1738851154361,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"Potential company&nbsp;,but the management fucked up&nbsp;","listText":"Potential company&nbsp;,but the management fucked up&nbsp;","text":"Potential company ,but the management fucked up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/400763440226984","repostId":"2509731232","repostType":2,"repost":{"id":"2509731232","kind":"highlight","weMediaInfo":{"introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the world’s largest and most trusted newswires.","home_visible":1,"media_name":"GlobeNewswire","id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"pubTimestamp":1738846800,"share":"https://ttm.financial/m/news/2509731232?lang=&edition=full_marsco","pubTime":"2025-02-06 21:00","market":"us","language":"en","title":"Tonix Pharmaceuticals Announces Positive Topline Results from Phase 1 Trial for TNX-1500, a Next Generation anti-CD40L mAb Candidate for Prevention of Kidney Transplant Rejection and Treatment of Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2509731232","media":"GlobeNewswire","summary":"Results from the Phase 1 single ascending dose study support proceeding to develop a Phase 2 trial for the prevention of kidney transplant rejection TNX-1500 blocked the primary and secondary antibody","content":"<html><body><p><em>Results from the Phase 1 single ascending dose study support proceeding to develop a Phase 2 trial for the prevention of kidney transplant rejection</em></p> <p><em>TNX-1500 blocked the primary and secondary antibody responses to a test antigen at the 10 mg/kg and 30 mg/kg i.v. doses </em></p> <p><em>TNX-1500 showed mean half-life of 34-38 days for the 10 mg/kg and 30 mg/kg doses supporting monthly dosing for future efficacy trials</em></p> <p><em>TNX-1500 was generally well-tolerated with a favorable safety profile</em></p> <p><em>Anti-CD40L has multiple potential indications in addition to solid organ and bone marrow transplantation including autoimmune diseases: potential pipeline in a product</em></p> <p>CHATHAM, N.J., Feb.  06, 2025  (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced positive topline results from its Phase 1, single ascending dose trial of TNX-1500 (Fc-modified humanized anti-CD40L monoclonal antibody, or mAb)* in healthy participants. The objectives of the Phase 1 trial were to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous TNX-1500, as well as to support dosing in a planned Phase 2 trial in kidney transplant recipients.</p> <p>“There remains a significant need for new agents with improved activity and safety to prevent transplant rejection and treat autoimmune diseases,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “First generation anti-CD40L mAb therapy, particularly ruplizumab (a.k.a., humanized 5c8 or BG9588) showed activity in modulating autoimmunity and rejection in allo- and xeno-transplantation but was limited by an increased risk of thrombosis.<sup>1</sup><sup>-3</sup> Tonix created TNX-1500, a next generation anti-CD40L mAb, by reengineering the Fc region of ruplizumab, to preserve activity with improved safety. The results of the Phase 1 study indicate that TNX-1500 has met these design objectives. We believe the results of this study and our prior animal studies<sup>4,5</sup> indicate that TNX-1500 is potentially best-in-class among next-generation anti-CD40L mAbs in development.”</p> <p>Gregory Sullivan, M.D., Chief Medical Officer of Tonix Pharmaceuticals said, “Topline results from the TNX-1500 Phase 1 study showed TNX-1500 at the 10 mg/kg and 30 mg/kg doses blocked both the primary and secondary antibody responses to a test antigen. The pharmacokinetic data support monthly dosing at doses of 10 mg/kg or above. Based on these findings, we are eager to advance this promising candidate into a Phase 2 efficacy study. We believe TNX-1500 has the potential to prevent organ transplant rejection and improve graft survival with reduced long-term toxicity burden relative to current immunosuppressive regimens.”</p> <p><u>Methods and Topline Results</u></p> <ul type=\"square\"><li><u>Dosing</u>: TNX-1500 solution was infused <em>i.v.</em> over a period of one hour to achieve doses of 3 mg/kg, 10 mg/kg, and 30 mg/kg. Participants were observed in the clinic for one day and followed with periodic clinic visits to Day 120.</li><li><u>Keyhole Limpet Hemocyanin (KLH) Challenge</u>: To evaluate the immune modulation potency of TNX-1500, participants received an antigen challenge with KLH (Immucothel<sup>®</sup>) administered subcutaneously (SC) on Day 2 and Day 29 of the study.</li><li><u>Disposition</u>: A total of 26 participants were enrolled in three Cohorts (3 mg/kg, 10 mg/kg, and 30 mg/kg). A total of 24 participants completed the study and two discontinued early (one placebo participant was lost to follow-up and one on TNX-1500 withdrew consent).</li><li><u>Tolerability</u>: TNX-1500 was generally well-tolerated with a favorable safety and tolerability profile. The only treatment-emergent adverse event (TEAE) occurring in ≥ 3 participants among all TNX-1500 groups was aphthous ulcer, occurring in one participant each in the 3 mg/kg, 10 mg/kg, and 30 mg/kg groups; all were rated as mild, possibly related, and resolved in 2-10 days. There were no TEAEs assessed as related to KLH administration. No TEAEs led to study discontinuation and there were no serious adverse events. There were no thromboembolic events, which were prespecified as TEAEs of special interest.</li><li><u>Pharmacodynamics</u>: TNX-1500 at 10 mg/kg and 30 mg/kg blocked both the primary and secondary anti-KLH Ab responses, evidenced by the mean Ab level at all sampled timepoints (through Day 120) being below the lower limit of quantitation (400 µg/L).  TNX-1500 at 3 mg/kg blocked the primary response to KLH Day 2 challenge and reduced the peak secondary response to KLH Day 29 challenge by approximately two thirds (69%) relative to the peak response to placebo.</li><li><u>Pharmacokinetics</u>: The mean (SD) half-life of TNX-1500 was: 3 mg/kg, 19.6 (9.29) days; 10 mg/kg, 37.8 (5.46) days; and 30 mg/kg, 33.7 (4.83) days.</li></ul> <p>Tonix plans to discuss these results with the U.S. Food and Drug Administration (FDA) in an End-of-Phase 1 meeting. Pending alignment with the FDA, a Phase 2 study of TNX-1500 in kidney transplant recipients will be pursued.</p> <p><strong>About TNX-1500</strong></p> <p>TNX-1500 (Fc-modified humanized anti-CD40L mAb) is a humanized monoclonal antibody that binds and functionally inhibits the CD40-ligand (CD40L), also known as CD154. TNX-1500 is being developed for the prevention of allograft and xenograft rejection, for the prevention of graft-versus-host disease (GvHD) after hematopoietic stem cell transplantation (HCT) and for the treatment of autoimmune diseases. Two published articles in the <em>American Journal of Transplantation</em> demonstrate TNX-1500 prevents rejection, prolongs survival and preserves graft function as a single agent or in combination with other drugs in non-human primate renal and heart allografts. <sup>4,5</sup></p> <p>*TNX-1500 is an investigational new biologic and is not approved for any indication</p> <p>Citations</p> <ol><li>Lederman S, et al, <em>J Exp Med</em>. 1992;175(4):1091-101. doi: 10.1084/jem.175.4.1091. PMID: 1348081; PMCID: PMC2119166.</li><li>Boumpas DT, et. al. <em>Arthritis Rheum</em>. 2003;48(3):719-27. doi: 10.1002/art.10856. PMID: 12632425.</li><li>Pierson RN 3rd, et al. <em>Transplantation</em>. 1999;68(11):1800-5. doi: 10.1097/00007890-199912150-00026. PMID: 10609959.</li><li>Lassiter G, et al. <em>Am J Transplant</em>. 2023;23(8):1171-1181. doi: 10.1016/j.ajt.2023.03.022.</li><li>Miura S, et al. <em>Am J Transplant</em>. 2023;23(8):1182-1193. doi: 10.1016/j.ajt.2023.03.025.<br/></li></ol> <p><strong>Tonix Pharmaceuticals Holding Corp.</strong><sup><strong>*</strong></sup></p> <p>Tonix is a fully-integrated biopharmaceutical company focused on transforming therapies for pain management and vaccines for public health challenges. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to advance TNX-102 SL, a product candidate for the management of fibromyalgia, for which an NDA was submitted based on two statistically significant Phase 3 studies for the management of fibromyalgia and for which a PDUFA (Prescription Drug User Fee act) goal date of August 15, 2025 has been assigned for a decision on marketing authorization. The FDA has also granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic in Phase 2 development designed to treat cocaine intoxication that has FDA Breakthrough Therapy designation, and its development is supported by a grant from the U.S. National Institute on Drug Abuse. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in infectious disease, including a vaccine for mpox, TNX-801. Tonix recently announced a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.</p> <p>* Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.</p> <p>Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.</p> <p>This press release and further information about Tonix can be found at www.tonixpharma.com.</p> <p><strong>Forward Looking Statements</strong></p> <p>Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.</p> <p><strong>Investor Contact</strong></p> <p>Jessica Morris<br/>Tonix Pharmaceuticals<br/>investor.relations@tonixpharma.com <br/>(862) 904-8182</p> <p>Peter Vozzo<br/>ICR Healthcare<br/>peter.vozzo@icrhealthcare.com <br/>(443) 213-0505</p> <p><strong>Media Contact</strong></p> <p>Ray Jordan<br/>Putnam Insights<br/>ray@putnaminsights.com<br/>(949) 245-5432</p> <p><strong>Indication and Usage</strong></p> <p>Zembrace® SymTouch® (sumatriptan succinate) injection (Zembrace) and Tosymra® (sumatriptan) nasal spray are prescription medicines used to treat acute migraine headaches with or without aura in adults who have been diagnosed with migraine.</p> <p>Zembrace and Tosymra are not used to prevent migraines. It is not known if Zembrace or Tosymra are safe and effective in children under 18 years of age.</p> <p><strong>Important Safety Information</strong></p> <p><strong>Zembrace and Tosymra can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop use and get emergency help if you have any signs of a heart attack:</strong></p> <ul type=\"disc\"><li>discomfort in the center of your chest that lasts for more than a few minutes or goes away and comes back</li><li>severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw</li><li>pain or discomfort in your arms, back, neck, jaw or stomach</li><li>shortness of breath with or without chest discomfort</li><li>breaking out in a cold sweat</li><li>nausea or vomiting</li><li>feeling lightheaded<br/></li></ul> <p>Zembrace and Tosymra are not for people with risk factors for heart disease (high blood pressure or cholesterol, smoking, overweight, diabetes, family history of heart disease) unless a heart exam shows no problem.</p> <p>Do not use Zembrace or Tosymra if you have:</p> <ul type=\"disc\"><li>history of heart problems</li><li>narrowing of blood vessels to your legs, arms, stomach, or kidney (peripheral vascular disease)</li><li>uncontrolled high blood pressure</li><li>hemiplegic or basilar migraines. If you are not sure if you have these, ask your provider.</li><li>had a stroke, transient ischemic attacks (TIAs), or problems with blood circulation</li><li>severe liver problems</li><li>taken any of the following medicines in the last 24 hours: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, ergotamines, or dihydroergotamine. Ask your provider for a list of these medicines if you are not sure.</li><li>are taking certain antidepressants, known as monoamine oxidase (MAO)-A inhibitors or it has been 2 weeks or less since you stopped taking a MAO-A inhibitor. Ask your provider for a list of these medicines if you are not sure.</li><li>an allergy to sumatriptan or any of the components of Zembrace or Tosymra<br/></li></ul> <p>Tell your provider about all of your medical conditions and medicines you take, including vitamins and supplements.</p> <p>Zembrace and Tosymra can cause dizziness, weakness, or drowsiness. If so, do not drive a car, use machinery, or do anything where you need to be alert.</p> <p>Zembrace and Tosymra may cause serious side effects including:</p> <ul type=\"disc\"><li>changes in color or sensation in your fingers and toes</li><li>sudden or severe stomach pain, stomach pain after meals, weight loss, nausea or vomiting, constipation or diarrhea, bloody diarrhea, fever</li><li>cramping and pain in your legs or hips; feeling of heaviness or tightness in your leg muscles; burning or aching pain in your feet or toes while resting; numbness, tingling, or weakness in your legs; cold feeling or color changes in one or both legs or feet</li><li>increased blood pressure including a sudden severe increase even if you have no history of high blood pressure</li><li>medication overuse headaches from using migraine medicine for 10 or more days each month. If your headaches get worse, call your provider.</li><li>serotonin syndrome, a rare but serious problem that can happen in people using Zembrace or Tosymra, especially when used with anti-depressant medicines called SSRIs or SNRIs. Call your provider right away if you have: mental changes such as seeing things that are not there (hallucinations), agitation, or coma; fast heartbeat; changes in blood pressure; high body temperature; tight muscles; or trouble walking.</li><li>hives (itchy bumps); swelling of your tongue, mouth, or throat</li><li>seizures even in people who have never had seizures before</li></ul> <p>The most common side effects of Zembrace and Tosymra include: pain and redness at injection site (Zembrance only); tingling or numbness in your fingers or toes; dizziness; warm, hot, burning feeling to your face (flushing); discomfort or stiffness in your neck; feeling weak, drowsy, or tired; application site (nasal) reactions (Tosymra only) and throat irritation (Tosymra only).</p> <p>Tell your provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of Zembrace and Tosymra. For more information, ask your provider.</p> <p>This is the most important information to know about Zembrace and Tosymra but is not comprehensive. For more information, talk to your provider and read the Patient Information and Instructions for Use. You can also visit https://www.tonixpharma.com or call 1-888-869-7633.</p> <p>You are encouraged to report adverse effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/NDY2ODBiZmQtYjM2MC00YTE4LWFhYzUtNWY0ODM3Mjg3NTBlLTEwMjI2ODU=/tiny/Tonix-Pharmaceuticals-Holding-.png\"/></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tonix Pharmaceuticals Announces Positive Topline Results from Phase 1 Trial for TNX-1500, a Next Generation anti-CD40L mAb Candidate for Prevention of Kidney Transplant Rejection and Treatment of Autoimmune Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTonix Pharmaceuticals Announces Positive Topline Results from Phase 1 Trial for TNX-1500, a Next Generation anti-CD40L mAb Candidate for Prevention of Kidney Transplant Rejection and Treatment of Autoimmune Diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1016364462\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">GlobeNewswire </p>\n<p class=\"h-time\">2025-02-06 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><em>Results from the Phase 1 single ascending dose study support proceeding to develop a Phase 2 trial for the prevention of kidney transplant rejection</em></p> <p><em>TNX-1500 blocked the primary and secondary antibody responses to a test antigen at the 10 mg/kg and 30 mg/kg i.v. doses </em></p> <p><em>TNX-1500 showed mean half-life of 34-38 days for the 10 mg/kg and 30 mg/kg doses supporting monthly dosing for future efficacy trials</em></p> <p><em>TNX-1500 was generally well-tolerated with a favorable safety profile</em></p> <p><em>Anti-CD40L has multiple potential indications in addition to solid organ and bone marrow transplantation including autoimmune diseases: potential pipeline in a product</em></p> <p>CHATHAM, N.J., Feb.  06, 2025  (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced positive topline results from its Phase 1, single ascending dose trial of TNX-1500 (Fc-modified humanized anti-CD40L monoclonal antibody, or mAb)* in healthy participants. The objectives of the Phase 1 trial were to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous TNX-1500, as well as to support dosing in a planned Phase 2 trial in kidney transplant recipients.</p> <p>“There remains a significant need for new agents with improved activity and safety to prevent transplant rejection and treat autoimmune diseases,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “First generation anti-CD40L mAb therapy, particularly ruplizumab (a.k.a., humanized 5c8 or BG9588) showed activity in modulating autoimmunity and rejection in allo- and xeno-transplantation but was limited by an increased risk of thrombosis.<sup>1</sup><sup>-3</sup> Tonix created TNX-1500, a next generation anti-CD40L mAb, by reengineering the Fc region of ruplizumab, to preserve activity with improved safety. The results of the Phase 1 study indicate that TNX-1500 has met these design objectives. We believe the results of this study and our prior animal studies<sup>4,5</sup> indicate that TNX-1500 is potentially best-in-class among next-generation anti-CD40L mAbs in development.”</p> <p>Gregory Sullivan, M.D., Chief Medical Officer of Tonix Pharmaceuticals said, “Topline results from the TNX-1500 Phase 1 study showed TNX-1500 at the 10 mg/kg and 30 mg/kg doses blocked both the primary and secondary antibody responses to a test antigen. The pharmacokinetic data support monthly dosing at doses of 10 mg/kg or above. Based on these findings, we are eager to advance this promising candidate into a Phase 2 efficacy study. We believe TNX-1500 has the potential to prevent organ transplant rejection and improve graft survival with reduced long-term toxicity burden relative to current immunosuppressive regimens.”</p> <p><u>Methods and Topline Results</u></p> <ul type=\"square\"><li><u>Dosing</u>: TNX-1500 solution was infused <em>i.v.</em> over a period of one hour to achieve doses of 3 mg/kg, 10 mg/kg, and 30 mg/kg. Participants were observed in the clinic for one day and followed with periodic clinic visits to Day 120.</li><li><u>Keyhole Limpet Hemocyanin (KLH) Challenge</u>: To evaluate the immune modulation potency of TNX-1500, participants received an antigen challenge with KLH (Immucothel<sup>®</sup>) administered subcutaneously (SC) on Day 2 and Day 29 of the study.</li><li><u>Disposition</u>: A total of 26 participants were enrolled in three Cohorts (3 mg/kg, 10 mg/kg, and 30 mg/kg). A total of 24 participants completed the study and two discontinued early (one placebo participant was lost to follow-up and one on TNX-1500 withdrew consent).</li><li><u>Tolerability</u>: TNX-1500 was generally well-tolerated with a favorable safety and tolerability profile. The only treatment-emergent adverse event (TEAE) occurring in ≥ 3 participants among all TNX-1500 groups was aphthous ulcer, occurring in one participant each in the 3 mg/kg, 10 mg/kg, and 30 mg/kg groups; all were rated as mild, possibly related, and resolved in 2-10 days. There were no TEAEs assessed as related to KLH administration. No TEAEs led to study discontinuation and there were no serious adverse events. There were no thromboembolic events, which were prespecified as TEAEs of special interest.</li><li><u>Pharmacodynamics</u>: TNX-1500 at 10 mg/kg and 30 mg/kg blocked both the primary and secondary anti-KLH Ab responses, evidenced by the mean Ab level at all sampled timepoints (through Day 120) being below the lower limit of quantitation (400 µg/L).  TNX-1500 at 3 mg/kg blocked the primary response to KLH Day 2 challenge and reduced the peak secondary response to KLH Day 29 challenge by approximately two thirds (69%) relative to the peak response to placebo.</li><li><u>Pharmacokinetics</u>: The mean (SD) half-life of TNX-1500 was: 3 mg/kg, 19.6 (9.29) days; 10 mg/kg, 37.8 (5.46) days; and 30 mg/kg, 33.7 (4.83) days.</li></ul> <p>Tonix plans to discuss these results with the U.S. Food and Drug Administration (FDA) in an End-of-Phase 1 meeting. Pending alignment with the FDA, a Phase 2 study of TNX-1500 in kidney transplant recipients will be pursued.</p> <p><strong>About TNX-1500</strong></p> <p>TNX-1500 (Fc-modified humanized anti-CD40L mAb) is a humanized monoclonal antibody that binds and functionally inhibits the CD40-ligand (CD40L), also known as CD154. TNX-1500 is being developed for the prevention of allograft and xenograft rejection, for the prevention of graft-versus-host disease (GvHD) after hematopoietic stem cell transplantation (HCT) and for the treatment of autoimmune diseases. Two published articles in the <em>American Journal of Transplantation</em> demonstrate TNX-1500 prevents rejection, prolongs survival and preserves graft function as a single agent or in combination with other drugs in non-human primate renal and heart allografts. <sup>4,5</sup></p> <p>*TNX-1500 is an investigational new biologic and is not approved for any indication</p> <p>Citations</p> <ol><li>Lederman S, et al, <em>J Exp Med</em>. 1992;175(4):1091-101. doi: 10.1084/jem.175.4.1091. PMID: 1348081; PMCID: PMC2119166.</li><li>Boumpas DT, et. al. <em>Arthritis Rheum</em>. 2003;48(3):719-27. doi: 10.1002/art.10856. PMID: 12632425.</li><li>Pierson RN 3rd, et al. <em>Transplantation</em>. 1999;68(11):1800-5. doi: 10.1097/00007890-199912150-00026. PMID: 10609959.</li><li>Lassiter G, et al. <em>Am J Transplant</em>. 2023;23(8):1171-1181. doi: 10.1016/j.ajt.2023.03.022.</li><li>Miura S, et al. <em>Am J Transplant</em>. 2023;23(8):1182-1193. doi: 10.1016/j.ajt.2023.03.025.<br/></li></ol> <p><strong>Tonix Pharmaceuticals Holding Corp.</strong><sup><strong>*</strong></sup></p> <p>Tonix is a fully-integrated biopharmaceutical company focused on transforming therapies for pain management and vaccines for public health challenges. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to advance TNX-102 SL, a product candidate for the management of fibromyalgia, for which an NDA was submitted based on two statistically significant Phase 3 studies for the management of fibromyalgia and for which a PDUFA (Prescription Drug User Fee act) goal date of August 15, 2025 has been assigned for a decision on marketing authorization. The FDA has also granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic in Phase 2 development designed to treat cocaine intoxication that has FDA Breakthrough Therapy designation, and its development is supported by a grant from the U.S. National Institute on Drug Abuse. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in infectious disease, including a vaccine for mpox, TNX-801. Tonix recently announced a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.</p> <p>* Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.</p> <p>Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.</p> <p>This press release and further information about Tonix can be found at www.tonixpharma.com.</p> <p><strong>Forward Looking Statements</strong></p> <p>Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.</p> <p><strong>Investor Contact</strong></p> <p>Jessica Morris<br/>Tonix Pharmaceuticals<br/>investor.relations@tonixpharma.com <br/>(862) 904-8182</p> <p>Peter Vozzo<br/>ICR Healthcare<br/>peter.vozzo@icrhealthcare.com <br/>(443) 213-0505</p> <p><strong>Media Contact</strong></p> <p>Ray Jordan<br/>Putnam Insights<br/>ray@putnaminsights.com<br/>(949) 245-5432</p> <p><strong>Indication and Usage</strong></p> <p>Zembrace® SymTouch® (sumatriptan succinate) injection (Zembrace) and Tosymra® (sumatriptan) nasal spray are prescription medicines used to treat acute migraine headaches with or without aura in adults who have been diagnosed with migraine.</p> <p>Zembrace and Tosymra are not used to prevent migraines. It is not known if Zembrace or Tosymra are safe and effective in children under 18 years of age.</p> <p><strong>Important Safety Information</strong></p> <p><strong>Zembrace and Tosymra can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop use and get emergency help if you have any signs of a heart attack:</strong></p> <ul type=\"disc\"><li>discomfort in the center of your chest that lasts for more than a few minutes or goes away and comes back</li><li>severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw</li><li>pain or discomfort in your arms, back, neck, jaw or stomach</li><li>shortness of breath with or without chest discomfort</li><li>breaking out in a cold sweat</li><li>nausea or vomiting</li><li>feeling lightheaded<br/></li></ul> <p>Zembrace and Tosymra are not for people with risk factors for heart disease (high blood pressure or cholesterol, smoking, overweight, diabetes, family history of heart disease) unless a heart exam shows no problem.</p> <p>Do not use Zembrace or Tosymra if you have:</p> <ul type=\"disc\"><li>history of heart problems</li><li>narrowing of blood vessels to your legs, arms, stomach, or kidney (peripheral vascular disease)</li><li>uncontrolled high blood pressure</li><li>hemiplegic or basilar migraines. If you are not sure if you have these, ask your provider.</li><li>had a stroke, transient ischemic attacks (TIAs), or problems with blood circulation</li><li>severe liver problems</li><li>taken any of the following medicines in the last 24 hours: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, ergotamines, or dihydroergotamine. Ask your provider for a list of these medicines if you are not sure.</li><li>are taking certain antidepressants, known as monoamine oxidase (MAO)-A inhibitors or it has been 2 weeks or less since you stopped taking a MAO-A inhibitor. Ask your provider for a list of these medicines if you are not sure.</li><li>an allergy to sumatriptan or any of the components of Zembrace or Tosymra<br/></li></ul> <p>Tell your provider about all of your medical conditions and medicines you take, including vitamins and supplements.</p> <p>Zembrace and Tosymra can cause dizziness, weakness, or drowsiness. If so, do not drive a car, use machinery, or do anything where you need to be alert.</p> <p>Zembrace and Tosymra may cause serious side effects including:</p> <ul type=\"disc\"><li>changes in color or sensation in your fingers and toes</li><li>sudden or severe stomach pain, stomach pain after meals, weight loss, nausea or vomiting, constipation or diarrhea, bloody diarrhea, fever</li><li>cramping and pain in your legs or hips; feeling of heaviness or tightness in your leg muscles; burning or aching pain in your feet or toes while resting; numbness, tingling, or weakness in your legs; cold feeling or color changes in one or both legs or feet</li><li>increased blood pressure including a sudden severe increase even if you have no history of high blood pressure</li><li>medication overuse headaches from using migraine medicine for 10 or more days each month. If your headaches get worse, call your provider.</li><li>serotonin syndrome, a rare but serious problem that can happen in people using Zembrace or Tosymra, especially when used with anti-depressant medicines called SSRIs or SNRIs. Call your provider right away if you have: mental changes such as seeing things that are not there (hallucinations), agitation, or coma; fast heartbeat; changes in blood pressure; high body temperature; tight muscles; or trouble walking.</li><li>hives (itchy bumps); swelling of your tongue, mouth, or throat</li><li>seizures even in people who have never had seizures before</li></ul> <p>The most common side effects of Zembrace and Tosymra include: pain and redness at injection site (Zembrance only); tingling or numbness in your fingers or toes; dizziness; warm, hot, burning feeling to your face (flushing); discomfort or stiffness in your neck; feeling weak, drowsy, or tired; application site (nasal) reactions (Tosymra only) and throat irritation (Tosymra only).</p> <p>Tell your provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of Zembrace and Tosymra. For more information, ask your provider.</p> <p>This is the most important information to know about Zembrace and Tosymra but is not comprehensive. For more information, talk to your provider and read the Patient Information and Instructions for Use. You can also visit https://www.tonixpharma.com or call 1-888-869-7633.</p> <p>You are encouraged to report adverse effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/NDY2ODBiZmQtYjM2MC00YTE4LWFhYzUtNWY0ODM3Mjg3NTBlLTEwMjI2ODU=/tiny/Tonix-Pharmaceuticals-Holding-.png\"/></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","BK4213":"石油与天然气的勘探与生产","BK4583":"猴痘概念","BK4135":"资产管理与托管银行","CNS":"科恩-斯蒂尔斯金融","TNXP":"Tonix Pharmaceuticals Holding Co","SD":"SandRidge Energy"},"source_url":"https://www.globenewswire.com/news-release/2025/02/06/3021973/28908/en/Tonix-Pharmaceuticals-Announces-Positive-Topline-Results-from-Phase-1-Trial-for-TNX-1500-a-Next-Generation-anti-CD40L-mAb-Candidate-for-Prevention-of-Kidney-Transplant-Rejection-an.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2509731232","content_text":"Results from the Phase 1 single ascending dose study support proceeding to develop a Phase 2 trial for the prevention of kidney transplant rejection TNX-1500 blocked the primary and secondary antibody responses to a test antigen at the 10 mg/kg and 30 mg/kg i.v. doses  TNX-1500 showed mean half-life of 34-38 days for the 10 mg/kg and 30 mg/kg doses supporting monthly dosing for future efficacy trials TNX-1500 was generally well-tolerated with a favorable safety profile Anti-CD40L has multiple potential indications in addition to solid organ and bone marrow transplantation including autoimmune diseases: potential pipeline in a product CHATHAM, N.J., Feb.  06, 2025  (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced positive topline results from its Phase 1, single ascending dose trial of TNX-1500 (Fc-modified humanized anti-CD40L monoclonal antibody, or mAb)* in healthy participants. The objectives of the Phase 1 trial were to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous TNX-1500, as well as to support dosing in a planned Phase 2 trial in kidney transplant recipients. “There remains a significant need for new agents with improved activity and safety to prevent transplant rejection and treat autoimmune diseases,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “First generation anti-CD40L mAb therapy, particularly ruplizumab (a.k.a., humanized 5c8 or BG9588) showed activity in modulating autoimmunity and rejection in allo- and xeno-transplantation but was limited by an increased risk of thrombosis.1-3 Tonix created TNX-1500, a next generation anti-CD40L mAb, by reengineering the Fc region of ruplizumab, to preserve activity with improved safety. The results of the Phase 1 study indicate that TNX-1500 has met these design objectives. We believe the results of this study and our prior animal studies4,5 indicate that TNX-1500 is potentially best-in-class among next-generation anti-CD40L mAbs in development.” Gregory Sullivan, M.D., Chief Medical Officer of Tonix Pharmaceuticals said, “Topline results from the TNX-1500 Phase 1 study showed TNX-1500 at the 10 mg/kg and 30 mg/kg doses blocked both the primary and secondary antibody responses to a test antigen. The pharmacokinetic data support monthly dosing at doses of 10 mg/kg or above. Based on these findings, we are eager to advance this promising candidate into a Phase 2 efficacy study. We believe TNX-1500 has the potential to prevent organ transplant rejection and improve graft survival with reduced long-term toxicity burden relative to current immunosuppressive regimens.” Methods and Topline Results Dosing: TNX-1500 solution was infused i.v. over a period of one hour to achieve doses of 3 mg/kg, 10 mg/kg, and 30 mg/kg. Participants were observed in the clinic for one day and followed with periodic clinic visits to Day 120.Keyhole Limpet Hemocyanin (KLH) Challenge: To evaluate the immune modulation potency of TNX-1500, participants received an antigen challenge with KLH (Immucothel®) administered subcutaneously (SC) on Day 2 and Day 29 of the study.Disposition: A total of 26 participants were enrolled in three Cohorts (3 mg/kg, 10 mg/kg, and 30 mg/kg). A total of 24 participants completed the study and two discontinued early (one placebo participant was lost to follow-up and one on TNX-1500 withdrew consent).Tolerability: TNX-1500 was generally well-tolerated with a favorable safety and tolerability profile. The only treatment-emergent adverse event (TEAE) occurring in ≥ 3 participants among all TNX-1500 groups was aphthous ulcer, occurring in one participant each in the 3 mg/kg, 10 mg/kg, and 30 mg/kg groups; all were rated as mild, possibly related, and resolved in 2-10 days. There were no TEAEs assessed as related to KLH administration. No TEAEs led to study discontinuation and there were no serious adverse events. There were no thromboembolic events, which were prespecified as TEAEs of special interest.Pharmacodynamics: TNX-1500 at 10 mg/kg and 30 mg/kg blocked both the primary and secondary anti-KLH Ab responses, evidenced by the mean Ab level at all sampled timepoints (through Day 120) being below the lower limit of quantitation (400 µg/L).  TNX-1500 at 3 mg/kg blocked the primary response to KLH Day 2 challenge and reduced the peak secondary response to KLH Day 29 challenge by approximately two thirds (69%) relative to the peak response to placebo.Pharmacokinetics: The mean (SD) half-life of TNX-1500 was: 3 mg/kg, 19.6 (9.29) days; 10 mg/kg, 37.8 (5.46) days; and 30 mg/kg, 33.7 (4.83) days. Tonix plans to discuss these results with the U.S. Food and Drug Administration (FDA) in an End-of-Phase 1 meeting. Pending alignment with the FDA, a Phase 2 study of TNX-1500 in kidney transplant recipients will be pursued. About TNX-1500 TNX-1500 (Fc-modified humanized anti-CD40L mAb) is a humanized monoclonal antibody that binds and functionally inhibits the CD40-ligand (CD40L), also known as CD154. TNX-1500 is being developed for the prevention of allograft and xenograft rejection, for the prevention of graft-versus-host disease (GvHD) after hematopoietic stem cell transplantation (HCT) and for the treatment of autoimmune diseases. Two published articles in the American Journal of Transplantation demonstrate TNX-1500 prevents rejection, prolongs survival and preserves graft function as a single agent or in combination with other drugs in non-human primate renal and heart allografts. 4,5 *TNX-1500 is an investigational new biologic and is not approved for any indication Citations Lederman S, et al, J Exp Med. 1992;175(4):1091-101. doi: 10.1084/jem.175.4.1091. PMID: 1348081; PMCID: PMC2119166.Boumpas DT, et. al. Arthritis Rheum. 2003;48(3):719-27. doi: 10.1002/art.10856. PMID: 12632425.Pierson RN 3rd, et al. Transplantation. 1999;68(11):1800-5. doi: 10.1097/00007890-199912150-00026. PMID: 10609959.Lassiter G, et al. Am J Transplant. 2023;23(8):1171-1181. doi: 10.1016/j.ajt.2023.03.022.Miura S, et al. Am J Transplant. 2023;23(8):1182-1193. doi: 10.1016/j.ajt.2023.03.025. Tonix Pharmaceuticals Holding Corp.* Tonix is a fully-integrated biopharmaceutical company focused on transforming therapies for pain management and vaccines for public health challenges. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to advance TNX-102 SL, a product candidate for the management of fibromyalgia, for which an NDA was submitted based on two statistically significant Phase 3 studies for the management of fibromyalgia and for which a PDUFA (Prescription Drug User Fee act) goal date of August 15, 2025 has been assigned for a decision on marketing authorization. The FDA has also granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic in Phase 2 development designed to treat cocaine intoxication that has FDA Breakthrough Therapy designation, and its development is supported by a grant from the U.S. National Institute on Drug Abuse. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in infectious disease, including a vaccine for mpox, TNX-801. Tonix recently announced a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults. * Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners. This press release and further information about Tonix can be found at www.tonixpharma.com. Forward Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof. Investor Contact Jessica MorrisTonix Pharmaceuticalsinvestor.relations@tonixpharma.com (862) 904-8182 Peter VozzoICR Healthcarepeter.vozzo@icrhealthcare.com (443) 213-0505 Media Contact Ray JordanPutnam Insightsray@putnaminsights.com(949) 245-5432 Indication and Usage Zembrace® SymTouch® (sumatriptan succinate) injection (Zembrace) and Tosymra® (sumatriptan) nasal spray are prescription medicines used to treat acute migraine headaches with or without aura in adults who have been diagnosed with migraine. Zembrace and Tosymra are not used to prevent migraines. It is not known if Zembrace or Tosymra are safe and effective in children under 18 years of age. Important Safety Information Zembrace and Tosymra can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop use and get emergency help if you have any signs of a heart attack: discomfort in the center of your chest that lasts for more than a few minutes or goes away and comes backsevere tightness, pain, pressure, or heaviness in your chest, throat, neck, or jawpain or discomfort in your arms, back, neck, jaw or stomachshortness of breath with or without chest discomfortbreaking out in a cold sweatnausea or vomitingfeeling lightheaded Zembrace and Tosymra are not for people with risk factors for heart disease (high blood pressure or cholesterol, smoking, overweight, diabetes, family history of heart disease) unless a heart exam shows no problem. Do not use Zembrace or Tosymra if you have: history of heart problemsnarrowing of blood vessels to your legs, arms, stomach, or kidney (peripheral vascular disease)uncontrolled high blood pressurehemiplegic or basilar migraines. If you are not sure if you have these, ask your provider.had a stroke, transient ischemic attacks (TIAs), or problems with blood circulationsevere liver problemstaken any of the following medicines in the last 24 hours: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, ergotamines, or dihydroergotamine. Ask your provider for a list of these medicines if you are not sure.are taking certain antidepressants, known as monoamine oxidase (MAO)-A inhibitors or it has been 2 weeks or less since you stopped taking a MAO-A inhibitor. Ask your provider for a list of these medicines if you are not sure.an allergy to sumatriptan or any of the components of Zembrace or Tosymra Tell your provider about all of your medical conditions and medicines you take, including vitamins and supplements. Zembrace and Tosymra can cause dizziness, weakness, or drowsiness. If so, do not drive a car, use machinery, or do anything where you need to be alert. Zembrace and Tosymra may cause serious side effects including: changes in color or sensation in your fingers and toessudden or severe stomach pain, stomach pain after meals, weight loss, nausea or vomiting, constipation or diarrhea, bloody diarrhea, fevercramping and pain in your legs or hips; feeling of heaviness or tightness in your leg muscles; burning or aching pain in your feet or toes while resting; numbness, tingling, or weakness in your legs; cold feeling or color changes in one or both legs or feetincreased blood pressure including a sudden severe increase even if you have no history of high blood pressuremedication overuse headaches from using migraine medicine for 10 or more days each month. If your headaches get worse, call your provider.serotonin syndrome, a rare but serious problem that can happen in people using Zembrace or Tosymra, especially when used with anti-depressant medicines called SSRIs or SNRIs. Call your provider right away if you have: mental changes such as seeing things that are not there (hallucinations), agitation, or coma; fast heartbeat; changes in blood pressure; high body temperature; tight muscles; or trouble walking.hives (itchy bumps); swelling of your tongue, mouth, or throatseizures even in people who have never had seizures before The most common side effects of Zembrace and Tosymra include: pain and redness at injection site (Zembrance only); tingling or numbness in your fingers or toes; dizziness; warm, hot, burning feeling to your face (flushing); discomfort or stiffness in your neck; feeling weak, drowsy, or tired; application site (nasal) reactions (Tosymra only) and throat irritation (Tosymra only). Tell your provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of Zembrace and Tosymra. For more information, ask your provider. This is the most important information to know about Zembrace and Tosymra but is not comprehensive. For more information, talk to your provider and read the Patient Information and Instructions for Use. You can also visit https://www.tonixpharma.com or call 1-888-869-7633. You are encouraged to report adverse effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.","news_type":1},"isVote":1,"tweetType":1,"viewCount":325,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":396359514776224,"gmtCreate":1737792483417,"gmtModify":1737792487513,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"Wishing everyone a happy new year <a href=\"https://ttm.financial/U/4156648821928502\"> @Kallu </a>and happy trading. <a href=\"https://ttm.financial/U/3527667667103859\"> @</a><a href=\"https://ttm.financial/U/3527667667103859\">TigerEvents</a><a href=\"https://ttm.financial/U/3527667667103859\"> </a>@","listText":"Wishing everyone a happy new year <a href=\"https://ttm.financial/U/4156648821928502\"> @Kallu </a>and happy trading. <a href=\"https://ttm.financial/U/3527667667103859\"> @</a><a href=\"https://ttm.financial/U/3527667667103859\">TigerEvents</a><a href=\"https://ttm.financial/U/3527667667103859\"> </a>@","text":"Wishing everyone a happy new year @Kallu and happy trading. @TigerEvents @","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/396359514776224","isVote":1,"tweetType":1,"viewCount":697,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":395542878499416,"gmtCreate":1737594771461,"gmtModify":1737594774594,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","listText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","text":"$Tonix Pharmaceuticals(TNXP)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/395542878499416","isVote":1,"tweetType":1,"viewCount":687,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":393911583731872,"gmtCreate":1737195896159,"gmtModify":1737196581965,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v> Underrated stock, potential to grow is there, but management fucked up. I really hope some big pharmacy would buy over this company.","listText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v> Underrated stock, potential to grow is there, but management fucked up. I really hope some big pharmacy would buy over this company.","text":"$Tonix Pharmaceuticals(TNXP)$ Underrated stock, potential to grow is there, but management fucked up. I really hope some big pharmacy would buy over this company.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/393911583731872","isVote":1,"tweetType":1,"viewCount":1025,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":389638531817520,"gmtCreate":1736134212056,"gmtModify":1736134216122,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"No ideas bro haha","listText":"No ideas bro haha","text":"No ideas bro haha","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/389638531817520","repostId":"389498675929496","repostType":1,"repost":{"id":389498675929496,"gmtCreate":1736132963538,"gmtModify":1736132967148,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/CNEY\">$CN Energy Group Inc.(CNEY)$ </a> why it's raising&nbsp;<a href=\"https://ttm.financial/U/4178332581629092\">@Boybabyrage </a>&nbsp;<a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT </a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/CNEY\">$CN Energy Group Inc.(CNEY)$ </a> why it's raising&nbsp;<a href=\"https://ttm.financial/U/4178332581629092\">@Boybabyrage </a>&nbsp;<a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT </a>&nbsp;","text":"$CN Energy Group Inc.(CNEY)$ why it's raising @Boybabyrage @TigerGPT","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/389498675929496","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":708,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":336147014119784,"gmtCreate":1723105421943,"gmtModify":1723112402020,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/RR\">$Richtech Robotics(RR)$ </a> Time to bring this stock up to $1++.&nbsp; It has the potential to rival Serve Robotics.","listText":"<a href=\"https://ttm.financial/S/RR\">$Richtech Robotics(RR)$ </a> Time to bring this stock up to $1++.&nbsp; It has the potential to rival Serve Robotics.","text":"$Richtech Robotics(RR)$ Time to bring this stock up to $1++. It has the potential to rival Serve Robotics.","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":116,"commentSize":28,"repostSize":1243,"link":"https://ttm.financial/post/336147014119784","isVote":1,"tweetType":1,"viewCount":25845,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4148225697711872","authorId":"4148225697711872","name":"HelixTrader","avatar":"https://community-static.tradeup.com/news/c36de01fdced41f046f9ad240d5a8ac2","crmLevel":1,"crmLevelSwitch":0,"idStr":"4148225697711872","authorIdStr":"4148225697711872"},"content":"it's already ahead of serv in both revenue and cash. If it takes off in meme value, it could easily chain react 1000% + from here","text":"it's already ahead of serv in both revenue and cash. If it takes off in meme value, it could easily chain react 1000% + from here","html":"it's already ahead of serv in both revenue and cash. If it takes off in meme value, it could easily chain react 1000% + from here"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":311262868045960,"gmtCreate":1716997545991,"gmtModify":1716997550514,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/FFIE\">$Faraday Future Intelligent Electric Inc.(FFIE)$ </a> Anyone thinks this stock still have hopes ? hahah&nbsp;","listText":"<a href=\"https://ttm.financial/S/FFIE\">$Faraday Future Intelligent Electric Inc.(FFIE)$ </a> Anyone thinks this stock still have hopes ? hahah&nbsp;","text":"$Faraday Future Intelligent Electric Inc.(FFIE)$ Anyone thinks this stock still have hopes ? hahah","images":[{"img":"https://community-static.tradeup.com/news/b685fd77efc4d9ffd03859704f317178","width":"860","height":"1252"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":48,"commentSize":4,"repostSize":447,"link":"https://ttm.financial/post/311262868045960","isVote":1,"tweetType":1,"viewCount":8639,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":333972593078288,"gmtCreate":1722569690499,"gmtModify":1722636601908,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/5E2.SI\">$Seatrium Ltd(5E2.SI)$ </a> why the stock price is down...I thought the company is doing much better this year&nbsp;","listText":"<a href=\"https://ttm.financial/S/5E2.SI\">$Seatrium Ltd(5E2.SI)$ </a> why the stock price is down...I thought the company is doing much better this year&nbsp;","text":"$Seatrium Ltd(5E2.SI)$ why the stock price is down...I thought the company is doing much better this year","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":67,"commentSize":13,"repostSize":547,"link":"https://ttm.financial/post/333972593078288","isVote":1,"tweetType":1,"viewCount":14348,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4103693145898130","authorId":"4103693145898130","name":"DanT","avatar":"https://community-static.tradeup.com/news/f005134b11d78113ad0b9f15d9fc61ed","crmLevel":5,"crmLevelSwitch":1,"idStr":"4103693145898130","authorIdStr":"4103693145898130"},"content":"You need to be patient with these companies who have long term contracts. Not overnight will do well","text":"You need to be patient with these companies who have long term contracts. Not overnight will do well","html":"You need to be patient with these companies who have long term contracts. Not overnight will do well"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":382562971017432,"gmtCreate":1734375969150,"gmtModify":1734375973420,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v> Let's go to the moon.","listText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v> Let's go to the moon.","text":"$Tonix Pharmaceuticals(TNXP)$ Let's go to the moon.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":10,"repostSize":68,"link":"https://ttm.financial/post/382562971017432","isVote":1,"tweetType":1,"viewCount":2614,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"content":"FDA Aprroved bro","text":"FDA Aprroved bro","html":"FDA Aprroved bro"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":320900765933848,"gmtCreate":1719366875815,"gmtModify":1719825934922,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/FFIE\">$Faraday Future Intelligent Electric Inc.(FFIE)$&nbsp;</a><v-v data-views=\"1\"></v-v> Something big is coming. Notice the cash inflow is greater than outflow now. Just a feeling. I know this is a meme stock ,but it has a potential to grow if they can sail through this storm.&nbsp; Updated : They just got MGO as their assurance auditor.&nbsp; https://www.businesswire.com/news/home/20240624546356/en/Faraday-Future-Announces-Appointment-of-New-Independent-Auditor","listText":"<a href=\"https://ttm.financial/S/FFIE\">$Faraday Future Intelligent Electric Inc.(FFIE)$&nbsp;</a><v-v data-views=\"1\"></v-v> Something big is coming. Notice the cash inflow is greater than outflow now. Just a feeling. I know this is a meme stock ,but it has a potential to grow if they can sail through this storm.&nbsp; Updated : They just got MGO as their assurance auditor.&nbsp; https://www.businesswire.com/news/home/20240624546356/en/Faraday-Future-Announces-Appointment-of-New-Independent-Auditor","text":"$Faraday Future Intelligent Electric Inc.(FFIE)$ Something big is coming. Notice the cash inflow is greater than outflow now. Just a feeling. I know this is a meme stock ,but it has a potential to grow if they can sail through this storm. Updated : They just got MGO as their assurance auditor. https://www.businesswire.com/news/home/20240624546356/en/Faraday-Future-Announces-Appointment-of-New-Independent-Auditor","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":98,"commentSize":7,"repostSize":264,"link":"https://ttm.financial/post/320900765933848","isVote":1,"tweetType":1,"viewCount":8835,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4138529394007362","authorId":"4138529394007362","name":"Kaylalingling","avatar":"https://community-static.tradeup.com/news/50f6ba4c12b5f5f6691f8e547f8fc89a","crmLevel":4,"crmLevelSwitch":1,"idStr":"4138529394007362","authorIdStr":"4138529394007362"},"content":"I also noticed that funds have flowed in, and it may be that I gave myself the fantasy of 😅 because I was too eager to pay back my capital.","text":"I also noticed that funds have flowed in, and it may be that I gave myself the fantasy of 😅 because I was too eager to pay back my capital.","html":"I also noticed that funds have flowed in, and it may be that I gave myself the fantasy of 😅 because I was too eager to pay back my capital."}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":343443819364656,"gmtCreate":1724878184483,"gmtModify":1724878188319,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$&nbsp;</a><v-v data-views=\"1\"></v-v> The result is already pretty good already, what do these investors expect...lol","listText":"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$&nbsp;</a><v-v data-views=\"1\"></v-v> The result is already pretty good already, what do these investors expect...lol","text":"$NVIDIA Corp(NVDA)$ The result is already pretty good already, what do these investors expect...lol","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":21,"commentSize":3,"repostSize":117,"link":"https://ttm.financial/post/343443819364656","isVote":1,"tweetType":1,"viewCount":3775,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"content":"I see a great potential in Q4 with the Blackwell chips. I am happy actually. They sell cheap cheap, I am buying more stocks","text":"I see a great potential in Q4 with the Blackwell chips. I am happy actually. They sell cheap cheap, I am buying more stocks","html":"I see a great potential in Q4 with the Blackwell chips. I am happy actually. They sell cheap cheap, I am buying more stocks"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":369683415142648,"gmtCreate":1731296283627,"gmtModify":1731296287246,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/CLSK\">$CleanSpark, Inc.(CLSK)$&nbsp;</a> When this one is opened ? any ideas?","listText":"<a href=\"https://ttm.financial/S/CLSK\">$CleanSpark, Inc.(CLSK)$&nbsp;</a> When this one is opened ? any ideas?","text":"$CleanSpark, Inc.(CLSK)$ When this one is opened ? any ideas?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":53,"link":"https://ttm.financial/post/369683415142648","isVote":1,"tweetType":1,"viewCount":1882,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3564741733611064","authorId":"3564741733611064","name":"sean00000000","avatar":"https://static.tigerbbs.com/e715cd75ee032f89dbd4a3d980a2a6eb","crmLevel":9,"crmLevelSwitch":0,"idStr":"3564741733611064","authorIdStr":"3564741733611064"},"content":"Most likely halted until they resolve warrant issues, heardsay tomorrow","text":"Most likely halted until they resolve warrant issues, heardsay tomorrow","html":"Most likely halted until they resolve warrant issues, heardsay tomorrow"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":349058687369272,"gmtCreate":1726249677271,"gmtModify":1726249680971,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/GOVX\">$GeoVax Labs Inc(GOVX)$&nbsp;</a> gg we lost&nbsp;","listText":"<a href=\"https://ttm.financial/S/GOVX\">$GeoVax Labs Inc(GOVX)$&nbsp;</a> gg we lost&nbsp;","text":"$GeoVax Labs Inc(GOVX)$ gg we lost","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":8,"repostSize":0,"link":"https://ttm.financial/post/349058687369272","isVote":1,"tweetType":1,"viewCount":973,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4170523205943252","authorId":"4170523205943252","name":"Barry obrien","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"idStr":"4170523205943252","authorIdStr":"4170523205943252"},"content":"how long before they help those and stocks sore","text":"how long before they help those and stocks sore","html":"how long before they help those and stocks sore"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":306514884591712,"gmtCreate":1715867897261,"gmtModify":1715867900906,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/GME\">$GameStop(GME)$ </a> I think the market is unstable at the moment, but this stock has potential to grow. It is worth a risk to hold at the moment.[Happy]&nbsp;&nbsp;","listText":"<a href=\"https://ttm.financial/S/GME\">$GameStop(GME)$ </a> I think the market is unstable at the moment, but this stock has potential to grow. It is worth a risk to hold at the moment.[Happy]&nbsp;&nbsp;","text":"$GameStop(GME)$ I think the market is unstable at the moment, but this stock has potential to grow. It is worth a risk to hold at the moment.[Happy]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":5,"repostSize":27,"link":"https://ttm.financial/post/306514884591712","isVote":1,"tweetType":1,"viewCount":2616,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3571830154340059","authorId":"3571830154340059","name":"DAL888","avatar":"https://static.tigerbbs.com/0802face5600deda9840d37e46bed674","crmLevel":2,"crmLevelSwitch":0,"idStr":"3571830154340059","authorIdStr":"3571830154340059"},"content":"buy and holdddddd!","text":"buy and holdddddd!","html":"buy and holdddddd!"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":381408217751624,"gmtCreate":1734148560583,"gmtModify":1734421010875,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"This year marks my first trading journey. First of all, thanks to the Tiger team for making this platform user-friendly even for a newbie like me. I started with small investments in reputable tech stocks like Nvidia, Google, Apple and Microsoft. It all played out well till the market crashed in August. I have learnt so much in this year including utilizing call and put options such as selling covered calls when the market is volatile and earning some incomes while holding my favorite stocks. The 2024 market has been a rollercoaster due to the US election and uncertainty in the economics. Now, things have settled down. I am expecting 2025 to be a great year for investors and traders. The stocks related to AI and Nuclear Energy should be in everyone's bookmarks.&nbsp; Long story short,","listText":"This year marks my first trading journey. First of all, thanks to the Tiger team for making this platform user-friendly even for a newbie like me. I started with small investments in reputable tech stocks like Nvidia, Google, Apple and Microsoft. It all played out well till the market crashed in August. I have learnt so much in this year including utilizing call and put options such as selling covered calls when the market is volatile and earning some incomes while holding my favorite stocks. The 2024 market has been a rollercoaster due to the US election and uncertainty in the economics. Now, things have settled down. I am expecting 2025 to be a great year for investors and traders. The stocks related to AI and Nuclear Energy should be in everyone's bookmarks.&nbsp; Long story short,","text":"This year marks my first trading journey. First of all, thanks to the Tiger team for making this platform user-friendly even for a newbie like me. I started with small investments in reputable tech stocks like Nvidia, Google, Apple and Microsoft. It all played out well till the market crashed in August. I have learnt so much in this year including utilizing call and put options such as selling covered calls when the market is volatile and earning some incomes while holding my favorite stocks. The 2024 market has been a rollercoaster due to the US election and uncertainty in the economics. Now, things have settled down. I am expecting 2025 to be a great year for investors and traders. The stocks related to AI and Nuclear Energy should be in everyone's bookmarks. Long story short,","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":33,"commentSize":3,"repostSize":1,"link":"https://ttm.financial/post/381408217751624","isVote":1,"tweetType":1,"viewCount":1353,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3501196737273098","authorId":"3501196737273098","name":"Tiger_comments","avatar":"https://community-static.tradeup.com/news/227887b200e9925968650d5db4a8bfb3","crmLevel":1,"crmLevelSwitch":0,"idStr":"3501196737273098","authorIdStr":"3501196737273098"},"content":"Thank you so much for choosing Tiger this year. 🐯 It’s users like you that make our community friendly! 🤝 Wishing you success in your investments in 2025. 📈 We hope every user can make profits! 💰🎉","text":"Thank you so much for choosing Tiger this year. 🐯 It’s users like you that make our community friendly! 🤝 Wishing you success in your investments in 2025. 📈 We hope every user can make profits! 💰🎉","html":"Thank you so much for choosing Tiger this year. 🐯 It’s users like you that make our community friendly! 🤝 Wishing you success in your investments in 2025. 📈 We hope every user can make profits! 💰🎉"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":343039023845632,"gmtCreate":1724768126775,"gmtModify":1724768130613,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TUYA\">$Tuya Inc.(TUYA)$ </a> Why does the stock drop? Wtffff","listText":"<a href=\"https://ttm.financial/S/TUYA\">$Tuya Inc.(TUYA)$ </a> Why does the stock drop? Wtffff","text":"$Tuya Inc.(TUYA)$ Why does the stock drop? Wtffff","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/343039023845632","isVote":1,"tweetType":1,"viewCount":412,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":373183558132104,"gmtCreate":1732154753974,"gmtModify":1732154758098,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v> Once the vaccine gets FDA approval, it will be skyrocket&nbsp;","listText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v> Once the vaccine gets FDA approval, it will be skyrocket&nbsp;","text":"$Tonix Pharmaceuticals(TNXP)$ Once the vaccine gets FDA approval, it will be skyrocket","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":5,"repostSize":2,"link":"https://ttm.financial/post/373183558132104","isVote":1,"tweetType":1,"viewCount":1120,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"content":"I read somewhere around Dec 2024 or early 2025","text":"I read somewhere around Dec 2024 or early 2025","html":"I read somewhere around Dec 2024 or early 2025"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":358564444115144,"gmtCreate":1728548473952,"gmtModify":1728548478238,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/5E2.SI\">$Seatrium Ltd(5E2.SI)$&nbsp;</a> dropping again??? why?","listText":"<a href=\"https://ttm.financial/S/5E2.SI\">$Seatrium Ltd(5E2.SI)$&nbsp;</a> dropping again??? why?","text":"$Seatrium Ltd(5E2.SI)$ dropping again??? why?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/358564444115144","isVote":1,"tweetType":1,"viewCount":825,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3578091555231876","authorId":"3578091555231876","name":"StreetCat","avatar":"https://community-static.tradeup.com/news/10240289f5373e15472b574f0d2f37a8","crmLevel":6,"crmLevelSwitch":1,"idStr":"3578091555231876","authorIdStr":"3578091555231876"},"content":"people say it is linked to oil price. must be drilling oil secretly","text":"people say it is linked to oil price. must be drilling oil secretly","html":"people say it is linked to oil price. must be drilling oil secretly"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":345293537226768,"gmtCreate":1725328172282,"gmtModify":1725328175792,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/5E2.SI\">$Seatrium Ltd(5E2.SI)$ </a> Can it hit $2? 🎯 :)&nbsp;","listText":"<a href=\"https://ttm.financial/S/5E2.SI\">$Seatrium Ltd(5E2.SI)$ </a> Can it hit $2? 🎯 :)&nbsp;","text":"$Seatrium Ltd(5E2.SI)$ Can it hit $2? 🎯 :)","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/345293537226768","isVote":1,"tweetType":1,"viewCount":891,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":316043645997128,"gmtCreate":1718184166094,"gmtModify":1718189719748,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"Amazon is looking to expand its business, thus during this time, we might not see the shoot in stock price yet as those money will be used in the infrastructure and building new data centres. Taiwan cloud infrastructure is a smart investment move.&nbsp;<a href=\"https://ttm.financial/S/AMZN\">$Amazon.com(AMZN)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","listText":"Amazon is looking to expand its business, thus during this time, we might not see the shoot in stock price yet as those money will be used in the infrastructure and building new data centres. Taiwan cloud infrastructure is a smart investment move.&nbsp;<a href=\"https://ttm.financial/S/AMZN\">$Amazon.com(AMZN)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","text":"Amazon is looking to expand its business, thus during this time, we might not see the shoot in stock price yet as those money will be used in the infrastructure and building new data centres. Taiwan cloud infrastructure is a smart investment move. $Amazon.com(AMZN)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":17,"commentSize":1,"repostSize":1,"link":"https://ttm.financial/post/316043645997128","repostId":"2442306120","repostType":4,"repost":{"id":"2442306120","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1718182560,"share":"https://ttm.financial/m/news/2442306120?lang=&edition=full_marsco","pubTime":"2024-06-12 16:56","market":"nz","language":"en","title":"Amazon to Invest Billions in Taiwan Cloud Infrastructure","url":"https://stock-news.laohu8.com/highlight/detail?id=2442306120","media":"Dow Jones","summary":"Amazon.com will invest billions of dollars in Taiwan over the next 15 years to build data centers, the latest global technology company to expand its footprint in Asia to meet the region's growing dem","content":"<p>Amazon.com will invest billions of dollars in Taiwan over the next 15 years to build data centers, the latest global technology company to expand its footprint in Asia to meet the region's growing demand for cloud services.</p><p>Amazon Web Services, the Seattle-based tech giant's cloud-computing arm, said late Tuesday that it will launch an AWS infrastructure region in Taiwan by early 2025 and invest billions of dollars \"as part of its long-term commitment.\"</p><p>The new infrastructure will enable customers to store data securely and run workloads with low latency from data centers located in Taiwan, it said.</p><p>AWS, which provides computing, storage and other services from data centers around the world, has been accelerating cloud-infrastructure spending globally, as Amazon Chief Executive Andy Jassy has reoriented the company to focus on artificial-intelligence innovations and to catch up with Microsoft, Google and others in the space.</p><p>AWS is Amazon's most profitable unit, with first-quarter results showing the segment's bottom line rose 17% from a year earlier to $25 billion. Amazon said the quarter's capital expenditure of $14 billion would be the low point for the year as it ramps up spending on AWS infrastructure and generative AI investment.</p><p>Taiwan has positioned itself as the center of the global AI race, with Taiwan Semiconductor Manufacturing Co.making advanced chips to run AI software.</p><p>Since the start of 2024, AWS has disclosed plans to spend $9 billion to expand its cloud services in Singapore, $15 billion to build cloud capacity in Japan and more than $5 billion each in Mexico and Saudi Arabia in the coming years.</p><p>Last year, AWS said it planned to spend almost $13 billion by 2030 to expand its data-center infrastructure in India, the world's most populous nation.</p><p>Meanwhile, Microsoft in May disclosed investment plans for Southeast Asia, while Google plans to invest $2 billion to establish its first data center in Malaysia to power cloud services.</p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amazon to Invest Billions in Taiwan Cloud Infrastructure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmazon to Invest Billions in Taiwan Cloud Infrastructure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-06-12 16:56</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Amazon.com will invest billions of dollars in Taiwan over the next 15 years to build data centers, the latest global technology company to expand its footprint in Asia to meet the region's growing demand for cloud services.</p><p>Amazon Web Services, the Seattle-based tech giant's cloud-computing arm, said late Tuesday that it will launch an AWS infrastructure region in Taiwan by early 2025 and invest billions of dollars \"as part of its long-term commitment.\"</p><p>The new infrastructure will enable customers to store data securely and run workloads with low latency from data centers located in Taiwan, it said.</p><p>AWS, which provides computing, storage and other services from data centers around the world, has been accelerating cloud-infrastructure spending globally, as Amazon Chief Executive Andy Jassy has reoriented the company to focus on artificial-intelligence innovations and to catch up with Microsoft, Google and others in the space.</p><p>AWS is Amazon's most profitable unit, with first-quarter results showing the segment's bottom line rose 17% from a year earlier to $25 billion. Amazon said the quarter's capital expenditure of $14 billion would be the low point for the year as it ramps up spending on AWS infrastructure and generative AI investment.</p><p>Taiwan has positioned itself as the center of the global AI race, with Taiwan Semiconductor Manufacturing Co.making advanced chips to run AI software.</p><p>Since the start of 2024, AWS has disclosed plans to spend $9 billion to expand its cloud services in Singapore, $15 billion to build cloud capacity in Japan and more than $5 billion each in Mexico and Saudi Arabia in the coming years.</p><p>Last year, AWS said it planned to spend almost $13 billion by 2030 to expand its data-center infrastructure in India, the world's most populous nation.</p><p>Meanwhile, Microsoft in May disclosed investment plans for Southeast Asia, while Google plans to invest $2 billion to establish its first data center in Malaysia to power cloud services.</p><p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2442306120","content_text":"Amazon.com will invest billions of dollars in Taiwan over the next 15 years to build data centers, the latest global technology company to expand its footprint in Asia to meet the region's growing demand for cloud services.Amazon Web Services, the Seattle-based tech giant's cloud-computing arm, said late Tuesday that it will launch an AWS infrastructure region in Taiwan by early 2025 and invest billions of dollars \"as part of its long-term commitment.\"The new infrastructure will enable customers to store data securely and run workloads with low latency from data centers located in Taiwan, it said.AWS, which provides computing, storage and other services from data centers around the world, has been accelerating cloud-infrastructure spending globally, as Amazon Chief Executive Andy Jassy has reoriented the company to focus on artificial-intelligence innovations and to catch up with Microsoft, Google and others in the space.AWS is Amazon's most profitable unit, with first-quarter results showing the segment's bottom line rose 17% from a year earlier to $25 billion. Amazon said the quarter's capital expenditure of $14 billion would be the low point for the year as it ramps up spending on AWS infrastructure and generative AI investment.Taiwan has positioned itself as the center of the global AI race, with Taiwan Semiconductor Manufacturing Co.making advanced chips to run AI software.Since the start of 2024, AWS has disclosed plans to spend $9 billion to expand its cloud services in Singapore, $15 billion to build cloud capacity in Japan and more than $5 billion each in Mexico and Saudi Arabia in the coming years.Last year, AWS said it planned to spend almost $13 billion by 2030 to expand its data-center infrastructure in India, the world's most populous nation.Meanwhile, Microsoft in May disclosed investment plans for Southeast Asia, while Google plans to invest $2 billion to establish its first data center in Malaysia to power cloud services.","news_type":1},"isVote":1,"tweetType":1,"viewCount":609,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":355426839191856,"gmtCreate":1727776213725,"gmtModify":1727777380145,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/RR\">$Richtech Robotics(RR)$&nbsp;</a>why this stock is fucked up so badly??? haha&nbsp;","listText":"<a href=\"https://ttm.financial/S/RR\">$Richtech Robotics(RR)$&nbsp;</a>why this stock is fucked up so badly??? haha&nbsp;","text":"$Richtech Robotics(RR)$ why this stock is fucked up so badly??? haha","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/355426839191856","isVote":1,"tweetType":1,"viewCount":806,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4183121921056332","authorId":"4183121921056332","name":"BKLI","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"idStr":"4183121921056332","authorIdStr":"4183121921056332"},"content":"No reason at all except “Short selling”. There is a lot of short selling on this tiny stock. Once they are happy then it will bounce back!","text":"No reason at all except “Short selling”. There is a lot of short selling on this tiny stock. Once they are happy then it will bounce back!","html":"No reason at all except “Short selling”. There is a lot of short selling on this tiny stock. Once they are happy then it will bounce back!"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":336067771666584,"gmtCreate":1723083884662,"gmtModify":1723083888083,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/5E2.SI\">$Seatrium Ltd(5E2.SI)$ </a> is this stock under manipulation?","listText":"<a href=\"https://ttm.financial/S/5E2.SI\">$Seatrium Ltd(5E2.SI)$ </a> is this stock under manipulation?","text":"$Seatrium Ltd(5E2.SI)$ is this stock under manipulation?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/336067771666584","isVote":1,"tweetType":1,"viewCount":892,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3582958699964444","authorId":"3582958699964444","name":"chew88","avatar":"https://static.tigerbbs.com/977c6fa02effca1970d78c5cedd70374","crmLevel":5,"crmLevelSwitch":0,"idStr":"3582958699964444","authorIdStr":"3582958699964444"},"content":"If the dealer doesn't move, the retail investors can't move!","text":"If the dealer doesn't move, the retail investors can't move!","html":"If the dealer doesn't move, the retail investors can't move!"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":345848620019824,"gmtCreate":1725462467600,"gmtModify":1725462471367,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/GOVX\">$GeoVax Labs Inc(GOVX)$&nbsp;</a><v-v data-views=\"1\"></v-v> Mpox is not going anywhere soon. The world needs vaccine.&nbsp;","listText":"<a href=\"https://ttm.financial/S/GOVX\">$GeoVax Labs Inc(GOVX)$&nbsp;</a><v-v data-views=\"1\"></v-v> Mpox is not going anywhere soon. The world needs vaccine.&nbsp;","text":"$GeoVax Labs Inc(GOVX)$ Mpox is not going anywhere soon. The world needs vaccine.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/345848620019824","isVote":1,"tweetType":1,"viewCount":1187,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3582720176678146","authorId":"3582720176678146","name":"Miracles7","avatar":"https://community-static.tradeup.com/news/9a4573fe8efe55602b87a02169ff13b9","crmLevel":8,"crmLevelSwitch":1,"idStr":"3582720176678146","authorIdStr":"3582720176678146"},"content":"But it keeps dropping","text":"But it keeps dropping","html":"But it keeps dropping"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":380306275107008,"gmtCreate":1733878069199,"gmtModify":1733878074024,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/CMRX\">$Chimerix(CMRX)$ </a> More to come :)","listText":"<a href=\"https://ttm.financial/S/CMRX\">$Chimerix(CMRX)$ </a> More to come :)","text":"$Chimerix(CMRX)$ More to come :)","images":[{"img":"https://community-static.tradeup.com/news/403acdd26f358c4bb5082ec742526cef","width":"830","height":"1501"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/380306275107008","isVote":1,"tweetType":1,"viewCount":560,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":401039356875440,"gmtCreate":1738937595203,"gmtModify":1738937598596,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"Hey guys, I think we still got hope. The balance sheet is now debt free. Looking good for me.&nbsp;&nbsp;<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","listText":"Hey guys, I think we still got hope. The balance sheet is now debt free. Looking good for me.&nbsp;&nbsp;<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","text":"Hey guys, I think we still got hope. The balance sheet is now debt free. Looking good for me. $Tonix Pharmaceuticals(TNXP)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/401039356875440","repostId":"2509745172","repostType":2,"repost":{"id":"2509745172","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1738935000,"share":"https://ttm.financial/m/news/2509745172?lang=&edition=full_marsco","pubTime":"2025-02-07 21:30","market":"sh","language":"en","title":"Press Release: Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash","url":"https://stock-news.laohu8.com/highlight/detail?id=2509745172","media":"Dow Jones","summary":"Company had $98.8 million in cash as of December 31, 2024; existing cash expected to fund planned operations into the first quarter of 2026. Company is debt-free after repaying mortgage on facilities. TNX-102 SL fibromyalgia FDA PDUFA goal date is August 15, 2025. $10.1 million in net sales from migraine products in 2024. CHATHAM, N.J., Feb. 07, 2025  -- Tonix Pharmaceuticals Holding Corp.  , a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, recently announced selected preliminary operating results for the year ended December 31, 2024, and certain preliminary financial condition information as of December 31, 2024. The above information is preliminary financial information for the year ended December 31, 2024 and subject to completion. The unaudited, estimated results for the year ended December 31, 2024 are preliminary and were prepared by the Company's management, based upon its estimates, a number of assumptions and current","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     Zembrace and Tosymra can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop use and get emergency help if you have any signs of a heart attack: \n</p>\n<pre>\n   -- discomfort in the center of your chest that lasts for more than a few \n      minutes or goes away and comes back \n \n   -- severe tightness, pain, pressure, or heaviness in your chest, throat, \n      neck, or jaw \n \n   -- pain or discomfort in your arms, back, neck, jaw or stomach \n \n   -- shortness of breath with or without chest discomfort \n \n   -- breaking out in a cold sweat \n \n   -- nausea or vomiting \n \n   -- feeling lightheaded \n</pre>\n<p>\n     Zembrace and Tosymra are not for people with risk factors for heart disease (high blood pressure or cholesterol, smoking, overweight, diabetes, family history of heart disease) unless a heart exam shows no problem. \n</p>\n<p>\n     Do not use Zembrace or Tosymra if you have: \n</p>\n<pre>\n   -- history of heart problems \n \n   -- narrowing of blood vessels to your legs, arms, stomach, or kidney \n      (peripheral vascular disease) \n \n   -- uncontrolled high blood pressure \n \n   -- hemiplegic or basilar migraines. If you are not sure if you have these, \n      ask your provider. \n \n   -- had a stroke, transient ischemic attacks (TIAs), or problems with blood \n      circulation \n \n   -- severe liver problems \n \n   -- taken any of the following medicines in the last 24 hours: almotriptan, \n      eletriptan, frovatriptan, naratriptan, rizatriptan, ergotamines, or \n      dihydroergotamine. Ask your provider for a list of these medicines if you \n      are not sure. \n \n   -- are taking certain antidepressants, known as monoamine oxidase (MAO)-A \n      inhibitors or it has been 2 weeks or less since you stopped taking a \n      MAO-A inhibitor. Ask your provider for a list of these medicines if you \n      are not sure. \n \n   -- an allergy to sumatriptan or any of the components of Zembrace or Tosymra \n</pre>\n<p>\n     Tell your provider about all of your medical conditions and medicines you take, including vitamins and supplements. \n</p>\n<p>\n     Zembrace and Tosymra can cause dizziness, weakness, or drowsiness. If so, do not drive a car, use machinery, or do anything where you need to be alert. \n</p>\n<p>\n     Zembrace and Tosymra may cause serious side effects including: \n</p>\n<pre>\n   -- changes in color or sensation in your fingers and toes \n \n   -- sudden or severe stomach pain, stomach pain after meals, weight loss, \n      nausea or vomiting, constipation or diarrhea, bloody diarrhea, fever \n \n   -- cramping and pain in your legs or hips; feeling of heaviness or tightness \n      in your leg muscles; burning or aching pain in your feet or toes while \n      resting; numbness, tingling, or weakness in your legs; cold feeling or \n      color changes in one or both legs or feet \n \n   -- increased blood pressure including a sudden severe increase even if you \n      have no history of high blood pressure \n \n   -- medication overuse headaches from using migraine medicine for 10 or more \n      days each month. If your headaches get worse, call your provider. \n \n   -- serotonin syndrome, a rare but serious problem that can happen in people \n      using Zembrace or Tosymra, especially when used with anti-depressant \n      medicines called SSRIs or SNRIs. Call your provider right away if you \n      have: mental changes such as seeing things that are not there \n      (hallucinations), agitation, or coma; fast heartbeat; changes in blood \n      pressure; high body temperature; tight muscles; or trouble walking. \n \n   -- hives (itchy bumps); swelling of your tongue, mouth, or throat \n \n   -- seizures even in people who have never had seizures before \n</pre>\n<p>\n     The most common side effects of Zembrace and Tosymra include: pain and redness at injection site (Zembrace only); tingling or numbness in your fingers or toes; dizziness; warm, hot, burning feeling to your face (flushing); discomfort or stiffness in your neck; feeling weak, drowsy, or tired; application site (nasal) reactions (Tosymra only) and throat irritation (Tosymra only). \n</p>\n<p>\n     Tell your provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of Zembrace and Tosymra. For more information, ask your provider. \n</p>\n<p>\n     This is the most important information to know about Zembrace and Tosymra but is not comprehensive. For more information, talk to your provider and read the Patient Information and Instructions for Use. You can also visit https://www.tonixpharma.com or call 1-888-869-7633. \n</p>\n<p>\n     You are encouraged to report adverse effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 07, 2025 08:30 ET (13:30 GMT)\n</p>\n</font>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Press Release: Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPress Release: Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-02-07 21:30</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     Zembrace and Tosymra can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop use and get emergency help if you have any signs of a heart attack: \n</p>\n<pre>\n   -- discomfort in the center of your chest that lasts for more than a few \n      minutes or goes away and comes back \n \n   -- severe tightness, pain, pressure, or heaviness in your chest, throat, \n      neck, or jaw \n \n   -- pain or discomfort in your arms, back, neck, jaw or stomach \n \n   -- shortness of breath with or without chest discomfort \n \n   -- breaking out in a cold sweat \n \n   -- nausea or vomiting \n \n   -- feeling lightheaded \n</pre>\n<p>\n     Zembrace and Tosymra are not for people with risk factors for heart disease (high blood pressure or cholesterol, smoking, overweight, diabetes, family history of heart disease) unless a heart exam shows no problem. \n</p>\n<p>\n     Do not use Zembrace or Tosymra if you have: \n</p>\n<pre>\n   -- history of heart problems \n \n   -- narrowing of blood vessels to your legs, arms, stomach, or kidney \n      (peripheral vascular disease) \n \n   -- uncontrolled high blood pressure \n \n   -- hemiplegic or basilar migraines. If you are not sure if you have these, \n      ask your provider. \n \n   -- had a stroke, transient ischemic attacks (TIAs), or problems with blood \n      circulation \n \n   -- severe liver problems \n \n   -- taken any of the following medicines in the last 24 hours: almotriptan, \n      eletriptan, frovatriptan, naratriptan, rizatriptan, ergotamines, or \n      dihydroergotamine. Ask your provider for a list of these medicines if you \n      are not sure. \n \n   -- are taking certain antidepressants, known as monoamine oxidase (MAO)-A \n      inhibitors or it has been 2 weeks or less since you stopped taking a \n      MAO-A inhibitor. Ask your provider for a list of these medicines if you \n      are not sure. \n \n   -- an allergy to sumatriptan or any of the components of Zembrace or Tosymra \n</pre>\n<p>\n     Tell your provider about all of your medical conditions and medicines you take, including vitamins and supplements. \n</p>\n<p>\n     Zembrace and Tosymra can cause dizziness, weakness, or drowsiness. If so, do not drive a car, use machinery, or do anything where you need to be alert. \n</p>\n<p>\n     Zembrace and Tosymra may cause serious side effects including: \n</p>\n<pre>\n   -- changes in color or sensation in your fingers and toes \n \n   -- sudden or severe stomach pain, stomach pain after meals, weight loss, \n      nausea or vomiting, constipation or diarrhea, bloody diarrhea, fever \n \n   -- cramping and pain in your legs or hips; feeling of heaviness or tightness \n      in your leg muscles; burning or aching pain in your feet or toes while \n      resting; numbness, tingling, or weakness in your legs; cold feeling or \n      color changes in one or both legs or feet \n \n   -- increased blood pressure including a sudden severe increase even if you \n      have no history of high blood pressure \n \n   -- medication overuse headaches from using migraine medicine for 10 or more \n      days each month. If your headaches get worse, call your provider. \n \n   -- serotonin syndrome, a rare but serious problem that can happen in people \n      using Zembrace or Tosymra, especially when used with anti-depressant \n      medicines called SSRIs or SNRIs. Call your provider right away if you \n      have: mental changes such as seeing things that are not there \n      (hallucinations), agitation, or coma; fast heartbeat; changes in blood \n      pressure; high body temperature; tight muscles; or trouble walking. \n \n   -- hives (itchy bumps); swelling of your tongue, mouth, or throat \n \n   -- seizures even in people who have never had seizures before \n</pre>\n<p>\n     The most common side effects of Zembrace and Tosymra include: pain and redness at injection site (Zembrace only); tingling or numbness in your fingers or toes; dizziness; warm, hot, burning feeling to your face (flushing); discomfort or stiffness in your neck; feeling weak, drowsy, or tired; application site (nasal) reactions (Tosymra only) and throat irritation (Tosymra only). \n</p>\n<p>\n     Tell your provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of Zembrace and Tosymra. For more information, ask your provider. \n</p>\n<p>\n     This is the most important information to know about Zembrace and Tosymra but is not comprehensive. For more information, talk to your provider and read the Patient Information and Instructions for Use. You can also visit https://www.tonixpharma.com or call 1-888-869-7633. \n</p>\n<p>\n     You are encouraged to report adverse effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 07, 2025 08:30 ET (13:30 GMT)\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TNXP":"Tonix Pharmaceuticals Holding Co"},"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2509745172","content_text":"Zembrace and Tosymra can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop use and get emergency help if you have any signs of a heart attack: \n\n\n   -- discomfort in the center of your chest that lasts for more than a few \n      minutes or goes away and comes back \n \n   -- severe tightness, pain, pressure, or heaviness in your chest, throat, \n      neck, or jaw \n \n   -- pain or discomfort in your arms, back, neck, jaw or stomach \n \n   -- shortness of breath with or without chest discomfort \n \n   -- breaking out in a cold sweat \n \n   -- nausea or vomiting \n \n   -- feeling lightheaded \n\n\n     Zembrace and Tosymra are not for people with risk factors for heart disease (high blood pressure or cholesterol, smoking, overweight, diabetes, family history of heart disease) unless a heart exam shows no problem. \n\n\n     Do not use Zembrace or Tosymra if you have: \n\n\n   -- history of heart problems \n \n   -- narrowing of blood vessels to your legs, arms, stomach, or kidney \n      (peripheral vascular disease) \n \n   -- uncontrolled high blood pressure \n \n   -- hemiplegic or basilar migraines. If you are not sure if you have these, \n      ask your provider. \n \n   -- had a stroke, transient ischemic attacks (TIAs), or problems with blood \n      circulation \n \n   -- severe liver problems \n \n   -- taken any of the following medicines in the last 24 hours: almotriptan, \n      eletriptan, frovatriptan, naratriptan, rizatriptan, ergotamines, or \n      dihydroergotamine. Ask your provider for a list of these medicines if you \n      are not sure. \n \n   -- are taking certain antidepressants, known as monoamine oxidase (MAO)-A \n      inhibitors or it has been 2 weeks or less since you stopped taking a \n      MAO-A inhibitor. Ask your provider for a list of these medicines if you \n      are not sure. \n \n   -- an allergy to sumatriptan or any of the components of Zembrace or Tosymra \n\n\n     Tell your provider about all of your medical conditions and medicines you take, including vitamins and supplements. \n\n\n     Zembrace and Tosymra can cause dizziness, weakness, or drowsiness. If so, do not drive a car, use machinery, or do anything where you need to be alert. \n\n\n     Zembrace and Tosymra may cause serious side effects including: \n\n\n   -- changes in color or sensation in your fingers and toes \n \n   -- sudden or severe stomach pain, stomach pain after meals, weight loss, \n      nausea or vomiting, constipation or diarrhea, bloody diarrhea, fever \n \n   -- cramping and pain in your legs or hips; feeling of heaviness or tightness \n      in your leg muscles; burning or aching pain in your feet or toes while \n      resting; numbness, tingling, or weakness in your legs; cold feeling or \n      color changes in one or both legs or feet \n \n   -- increased blood pressure including a sudden severe increase even if you \n      have no history of high blood pressure \n \n   -- medication overuse headaches from using migraine medicine for 10 or more \n      days each month. If your headaches get worse, call your provider. \n \n   -- serotonin syndrome, a rare but serious problem that can happen in people \n      using Zembrace or Tosymra, especially when used with anti-depressant \n      medicines called SSRIs or SNRIs. Call your provider right away if you \n      have: mental changes such as seeing things that are not there \n      (hallucinations), agitation, or coma; fast heartbeat; changes in blood \n      pressure; high body temperature; tight muscles; or trouble walking. \n \n   -- hives (itchy bumps); swelling of your tongue, mouth, or throat \n \n   -- seizures even in people who have never had seizures before \n\n\n     The most common side effects of Zembrace and Tosymra include: pain and redness at injection site (Zembrace only); tingling or numbness in your fingers or toes; dizziness; warm, hot, burning feeling to your face (flushing); discomfort or stiffness in your neck; feeling weak, drowsy, or tired; application site (nasal) reactions (Tosymra only) and throat irritation (Tosymra only). \n\n\n     Tell your provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of Zembrace and Tosymra. For more information, ask your provider. \n\n\n     This is the most important information to know about Zembrace and Tosymra but is not comprehensive. For more information, talk to your provider and read the Patient Information and Instructions for Use. You can also visit https://www.tonixpharma.com or call 1-888-869-7633. \n\n\n     You are encouraged to report adverse effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. \n\n\n  (END) Dow Jones Newswires\n\n\n  February 07, 2025 08:30 ET (13:30 GMT)","news_type":1},"isVote":1,"tweetType":1,"viewCount":871,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}